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CHAPTER I 
 
INTRODUCTION 
 
 Although its base rate is low compared to many other childhood diseases, cancer 
remains the leading cause of disease-related death of children in the United States.  
Approximately 1,560 children are expected to die from cancer this year, and an estimated 
9,500 children under the age of 14 will receive a new cancer diagnosis (American Cancer 
Society, 2006).  Acute lymphocytic leukemia (ALL) is the most common form of 
childhood cancer, accounting for nearly one-third of all diagnoses (American Cancer 
Society, 2006).  An invariably fatal disease prior to 1960 (Mulhern, 1994), ALL now has 
a five-year survival rate of over 70% owing to the introduction and ongoing modification 
of powerful treatment protocols, which not only destroy leukemic cells in the bone 
marrow, organs, and cerebrospinal fluid (CSF) but also prevent disease relapse in the 
central nervous system (i.e., CNS prophylaxis; Smith, Ries, Gurney, & Ross, 2004).   
As a result of these advances in treatment, the majority of children diagnosed with 
ALL are living well into adulthood, and the issue of managing the long-term sequelae of 
treatment and preserving quality of life of childhood ALL patients and survivors has 
become a major focus of research and clinical practice.  Known long-term effects of 
treatment for childhood ALL can include hormone deficiencies, infertility, pulmonary 
fibrosis and inflammation, kidney disease, osteopenia, cardiac complications, dental 
abnormalities, and even the development of second cancers (American Cancer Society, 
2006).   It is no surprise that the Childhood Cancer Survivorship Study (CCSS), a 
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multicenter cohort study of the late effects of childhood cancer treatment, found that adult 
survivors of childhood ALL reported experiencing significantly more overall physical 
and mental health problems, activity limitations, and functional impairment compared to 
adult siblings with no history of cancer (Ness et al., 2005; Hudson et al., 2003; See 
Robison et al., 2005 for a review).      
One important long-term consequence of ALL treatment that has been observed is 
impaired neurocognitive functioning.  Declines in overall intellectual ability (e.g., 
Mulhern, Ochs, & Fairclough, 1992; see Cousens, Waters, Said, & Stevens, 1988 for 
early meta-analytic review), academic performance (e.g., Anderson et al., 2000), memory 
and learning (e.g., Hill et al., 1997), attention and concentration (e.g., Lockwood, Bell, & 
Colegrove, 1999), information processing speed (Cousens et al., 1991), visuospatial skill 
(e.g., Espy et al., 2001), psychomotor functioning (e.g., Kaleita et al., 1999), executive 
functioning (e.g., Anderson et al., 1997) and language skills (e.g., Buttsworth, Murdoch, 
& Ozanne, 1993) are among the adverse neurocognitive outcomes reported in the 
literature.  A recently published meta-analytic review of the literature on the 
neurocognitive effects of treatment for childhood ALL found that when compared to 
control groups composed of healthy peers, siblings, or children treated for solid tumors or 
other chronic illness, ALL survivors experienced significant declines in both global and 
specific domains of neurocognitive function (Campbell et al., in press).  The effect sizes 
ranged from small to moderate (g = -.34 to -.71) and were in the negative direction, 
indicating consistent deficits for groups of children treated for ALL across all nine 
neurocognitive domains assessed: Overall Cognitive Functioning (which includes scores 
on measures of verbal, performance, and full scale intelligence), Academic Achievement 
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(which includes Reading, Arithmetic, and Spelling Achievement), Attention, Executive 
Function, Verbal Memory, Visuospatial Memory, Visuospatial Skill, Psychomotor Skill, 
and Information Processing Speed. 
Impairment in cognitive development and function holds clear implications for 
disruption in academic achievement and learning.  However, cognitive impairments as a 
result of cancer treatment may also have ramifications for social and emotional 
development.  Specifically, the current study focused on the broad higher order 
neurocognitive domain of executive function, as it has been shown to underlie emotion 
regulation and the utilization of adaptive coping mechanisms in children (Copeland & 
Compas, 2007).  If this is indeed the case, then it would be expected that impaired 
executive function as a result of ALL treatment could delay the development of or erode 
previously developed skills needed to regulate emotions and cope with stressful 
situations.  Further, because children who are unable to appropriately respond to stressful 
situations are considered to be at higher risk for developing symptoms of 
psychopathology (Compas et al. 2001), it follows that an indirect consequence of ALL 
treatment could be the onset or increase in emotional and behavioral problems in 
survivors of childhood cancer.  This study examined the links among executive function, 
coping strategies, and emotional and behavioral outcomes, in children and adolescents 
who have completed treatment for ALL.   
Before going on to describe the current study, I first provide an overview of basic 
information on childhood ALL and its treatment, as well as a summary of the 
neurophysiological and neurocognitive changes associated with childhood ALL 
treatment.  I then proceed to discuss the model of coping that is employed in the proposed 
 3
study and further explain its relation to executive function and self-regulation.  Lastly, I 
state the hypotheses and describe the method and results of the present study. 
 
Pediatric ALL: Disease and Treatment Overview 
 Approximately 75% of all childhood leukemia diagnoses are acute lymphocytic 
leukemia (ALL), a disease in which immature lymphocytes (i.e., white blood cells) 
rapidly proliferate and accrue in the bone marrow and eventually spread to the blood, 
meninges, lymph nodes, testicles in boys, and vital organs throughout the body (National 
Cancer Institute, 2004).  As leukemic cells accumulate, the cells that typically carry 
oxygen through the body (red blood cells), clot blood (platelets), and fight infection 
(normal white blood cells) are crowded out of the bone marrow and are unable to carry 
out their normal functions properly.  Consequently, the most common signs and 
symptoms children with ALL present with include bruising, bleeding, pallor, fatigue, 
fever, bone pain, and anemia.  While these symptoms and an abnormal blood cell count 
may be suggestive of the disease, a bone marrow sample drawn from the hip or sternum 
is necessary to make a definitive diagnosis of ALL.  In addition, cerebrospinal fluid 
(CSF) taken from the spine via lumbar puncture must also be tested to determine whether 
the disease has advanced to the CNS (National Cancer Institute, 2004).   
Once a diagnosis of ALL has been made the risk for relapse is estimated in order 
to determine what is likely to be the most effective course of treatment.  A number of 
factors are taken into account to determine prognosis, such as the child’s age (children 2-
10 years of age have better outcomes on average), sex (girls have higher remission and 
cure rates than boys), white blood cell count, certain genetic mutations (e.g., Philadelphia 
 4
chromosome), and the extent to which the disease has spread (National Cancer Institute, 
2004).  Children considered “high-risk” because they have a number of risk factors 
receive the most aggressive forms of treatment, which consequently are most likely to 
have adverse long-term effects, while children with a relatively good prognosis (i.e., 
“standard-risk”) are spared the most toxic of therapies.   
The current standard of care for the treatment of childhood ALL involves the 
administration of multiple chemotherapy drugs at specifically scheduled intervals over a 
period of two to three years.  Treatment occurs in four phases.  During the induction 
phase, remission of the disease is achieved by means of systemic chemotherapy (i.e., 
chemotherapy administered intravenously, intramuscularly, or orally), which destroys 
leukemic cells located in bone marrow, liver, spleen, and lymph nodes.  However, 
because these drugs cannot adequately infiltrate the blood-brain barrier, occult leukemic 
cells may remain in the CSF.  Treatment administered directly to the CNS (i.e., CNS 
prophylaxis) during the second phase of treatment is necessary to eradicate these cells 
and prevent future leukemia relapse in the CNS (National Cancer Institute, 2004).   Next, 
children undergo consolidation or intensification, during which high-dose chemotherapy 
drugs are employed in order to wipe out any remaining leukemic cells in the body.  The 
fourth stage of treatment is referred to as maintenance therapy.  At this final stage 
patients are administered lower doses of chemotherapy drugs for approximately two to 
three years to prevent leukemia relapse (National Cancer Institute, 2004).  While 
systemic therapies at various stages of treatment as well as the disease itself surely 
contribute to adverse long-term outcomes in survivors of childhood ALL, CNS 
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prophylaxis, which is discussed in the following section, may be the primary cause of 
neurocognitive sequelae.   
Although only 3% of childhood ALL patients present with occult leukemic cells 
in the CSF at the time of diagnosis, more than 50% of patients will develop CNS 
involvement if they do not receive CNS prophylaxis (National Cancer Institute, 2004).  
Consequently, all children diagnosed with ALL receive treatment designed to eradicate 
present CNS involvement and to prevent leukemia from developing in the CNS, in an 
effort to maximize their chance for survival.  For low- and standard-risk patients the drug 
methotrexate alone or in combination with other chemotherapy, including corticosteroids, 
is administered directly into the spinal fluid by means of a lumbar puncture (i.e., 
intrathecally).  Until full-brain or cranial irradiation therapy (CRT) was identified as a 
major cause of neurocognitive sequelae, most children diagnosed with ALL also received 
CRT as a part of CNS prophylaxis.  Due to its known toxicity in the developing brain, 
CRT is now reserved for children with CNS involvement at diagnosis, relapsed patients, 
and children at very high risk for relapse (Brown et al. 1996).  Although most no longer 
receive CRT, children with ALL remain at risk for declines in neurocognitive functioning 
because intrathecal methotrexate, the standard CNS prophylactic treatment has also been 
deemed as neurotoxic based on the results of some previous studies (see Campbell et al., 
in press for review).   
Corticosteroids are usually incorporated in standard treatment protocols for 
childhood ALL and other types of cancer.  Because of their anti-inflammatory properties, 
corticosteroids target and destroy white blood cells, and in the case of ALL, leukemic 
cells.  Prednisone and dexamethasone are the most commonly used steroids and are 
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administered in conjunction with vincristine and other chemotherapy drugs.  Because it is 
better able to penetrate the blood-brain barrier as a CNS prophylactic agent, 
dexamethasone is thought to be superior to prednisone in its ability to prevent CNS 
relapse (e.g., Kaspers et al., 1996).  However, some studies have shown that 
dexamethasone increases children’s risk of developing long-term neurocognitive sequelae 
to a greater degree than prednisone and so use of dexamethasone in children has been 
hotly contested.  In one of these studies, Waber and colleagues (2000) compared two 
ALL treatment groups: one received dexamethasone whereas the other received 
prednisone, both in conjunction to other modes of treatment as usual.  Results showed 
that the dexamethasone group performed significantly more poorly on tests of reading 
and mathematical academic achievement, working memory, and visuospatial skill and 
memory even after other treatment differences or effects were taken into account (Waber 
et al., 2000).    Clinical trials continue to be conducted to determine whether the benefits 
of dexamethasone outweigh its risks in comparison with prednisone.  
Although the majority of children diagnosed with ALL are successfully treated, a 
small number of patients will experience a relapse of their disease.  Many of these 
children will respond well to a second intensive course of chemotherapy and CRT; 
however, the few who relapse early on during their initial course of treatment or whose 
ALL recurs several times may require stem-cell transplantation (SCT).  This procedure 
involves harvesting bone marrow or stem cells from the patient (i.e., autologous) or from 
a matched donor (i.e., allogenic).  The child then undergoes high dose chemotherapy and 
sometimes full body irradiation in order to destroy all remaining leukemic cells; however, 
normal bone marrow and immune system cells are also killed in the process.  After the 
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SCT is performed, the child must stay in an environment free of pathogens due to 
chemotherapy-induced immunosuppression and is given supportive therapies to 
compensate for their deficient normal cells.  Many complications, such as graft-versus-
host disease and life-threatening infections, can result from SCT.  In addition, most 
children suffer painful acute symptoms (e.g., mucositis) and some will experience 
disabling or even life-threatening late effects (cataracts; organ damage).  Given their 
exposure to more neurotoxic treatments for a longer duration, children who relapse or 
undergo SCT may also be at even greater risk for developing neurocognitive deficits than 
children who were successfully treated following initial diagnosis (see Copeland, 1992 
for review; Cool, 1996).  For that reason, patients who experienced relapse or underwent 
SCT were considered beyond the scope of the current study. 
 
Neurophysiological and Neurocognitive Changes Associated with ALL Treatment 
Research has estimated that 16%-52% of children treated for ALL have at least 
one brain abnormality detected by magnetic resonance imaging (MRI) and computerized 
cranial tomography (CCT) scans (e.g., Hertzberg et al., 1997, Porto et al., 2004).  
According to Hertzberg and colleagues (1997) there are four distinct types of brain 
changes associated with CNS prophylaxis, including leukoencephalopathy and subacute 
necrotizing leukomyelopathy, both of which involve destruction of white matter; 
mineralizing microangiopathy (i.e., calcifications); and secondary CNS tumors.  Other 
studies have also identified enlargement of ventricles, cortical atrophy, and 
cerebrovascular problems (e.g., strokes; hemorrhage) as a result of ALL treatment 
(Paakko et al., 1994; Hertzberg et al. 1997; Porto et al., 2004).  There is evidence that 
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these changes are transient and may be temporally related to the administration of certain 
treatments, such as intermediate- or high-dose methotrexate (e.g., Chu et al. 2003; 
Paakko et al. 1992); however, their functional consequences may be permanent.  
Although direct relationships between structural changes and neurocognitive functioning 
remain unclear, findings from imaging studies paired with current knowledge of normal 
brain development could provide insight into the underlying causes of specific deficits 
exhibited by childhood ALL survivors.   
Currently, the most widely studied treatment-induced brain abnormality and 
possibly the one with the most significant neurocognitive implications is the degeneration 
of white matter and disruption of myelination.  Oligodendrocytes, a type of glial cell, 
produce myelin, which insulates neural pathways in the central nervous system in order 
to speed the transmission of information throughout the brain.  Myelination begins during 
gestation and continues through adolescence and into early adulthood (Luna & Sweeney, 
2004).  Thus, because the cells producing myelin, particularly in the frontal lobe and 
basal ganglia, are still developing throughout childhood and adolescence, it is likely that 
they are particularly vulnerable to treatments that are meant to target rapidly proliferating 
leukemic cells and are administered directly to the developing CNS.     
The cerebral hemispheres eventually become densely packed with white matter 
tracts that provide connections among cortical and subcortical structures (Lezak, 
Howieson, & Loring, 2004).  The ratio of white matter to gray matter is even greater in 
the right hemisphere where it is thought to be mainly involved in processing and 
integrating visuospatial information and novel stimuli, coordinating movement, 
emotional understanding and expression, among other nonverbal functions (Rourke, 
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1987; Goldberg & Costa, 1981).  Consequently, the functions primarily conducted in the 
right hemisphere would logically be most severely affected by abnormal or damaged 
white matter and could result in signs and symptoms consistent with nonverbal learning 
disabilities (NVLD), including impairments in the following domains:  psychomotor 
coordination, visuospatial ability, visual-motor integration, nonverbal reasoning, 
attention, mathematical achievement, social skills, and emotionality (Rourke & Tsatsanis, 
1996; Picard & Rourke, 1995).  Previous research studies have identified subtle deficits 
consistent with NLD syndrome in children treated for ALL, providing evidence that the 
white matter changes in the right hemisphere that occur as a result of CNS prophylaxis is 
indeed associated with specific neurocognitive sequelae (for review, see Picard & 
Rourke, 1995).   
Results from several previous studies have also suggested that children treated for 
ALL experience problems with executive functioning (e.g., Anderson, Godber, Smibert, 
& Ekert, 1997; Espy et al., 2001; see Campbell et al., in press, for a meta-analytic 
review), the set of higher order cognitive processes that includes planning, mental 
flexibility, initiation of behavior, behavioral inhibition, goal-directed behavior, working 
memory, and attention (Lezak, Howieson, & Loring, 2004).   Impaired executive 
functioning is usually associated with damage to the prefrontal cortex, which happens to 
be the last area of the brain to become fully myelinated.  The gradual emergence of the 
executive functions parallels the process of myelination, with both processes continuing 
into adulthood.  Thus, disruption of myelination or damage to white matter caused by 
CNS prophylaxis during childhood or adolescence could prevent or inhibit the normal 
development of executive functions.  This theory has been supported by studies that have 
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found symptoms of attention deficit hyperactivity disorder (ADHD) in children who had 
received treatment for ALL, specifically decreased attention and working memory, as 
well as slowed information processing speed (e.g., Schatz et al. 2000).  As might be 
expected given these treatment-induced symptoms, methylphenidate, the standard 
treatment for children with ADHD, has been shown to improve attention in long-term 
childhood ALL survivors (Mulhern et al. 2004).   
To summarize, several types of neurophysiological changes have been identified 
in children treated for ALL via neuro-imaging techniques.  However, demyelination and 
damage to white matter tracts appear to have the most likely functional implications 
based on research studies that have found impaired executive functioning and NLD-like 
deficits in ALL survivors.  These, among other neurocognitive problems that have been 
found in previous research, may be experienced on some level by all ALL survivors, but 
some children appear to be more susceptible to such treatment effects.  The next section 
will discuss putative demographic and medical variables that increase children’s 
vulnerability for neurocognitive effects.   
 
Risk Factors for Developing Neurocognitive Sequelae of Pediatric ALL 
 Several potential risk factors for developing neurocognitive impairment have been 
found in previous studies of children treated for ALL.  First, young age at diagnosis, 
especially during the first year of life, is considered to be a major risk factor for 
neurocognitive sequelae.  Infants are especially vulnerable to CNS involvement and 
relapse and are consequently given additional CNS prophylaxis to improve their 
prognosis.  Therefore, it is thought that infant patients are at greater risk for long-term 
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neurocognitive sequelae given the neurotoxicity of treatment and a rapidly developing 
brain.  However, contrary to this hypothesis, in a study of 30 children who were treated 
for ALL during the first year of life, an average of 5 years prior to testing, cognitive 
functioning as measured by the McCarthy Scales of Children’s Abilities was found to fall 
well within the average range compared to normative data (Kaleita, Reaman, MacLean, 
Sather, & Whitt, 1999).   
In contrast to the Kaleita et al. (1999) study, empirical evidence from other 
studies has suggested greater vulnerability to neurocognitive effects in children less than 
five years of age at diagnosis. For instance, Copeland and colleagues (1996) found a 
significant negative correlation between age at diagnosis and performance on perceptual-
motor tasks, such as the Beery Visual-Motor Integration Test and the Block Design 
subtest of the Wechsler Intelligence Scale for Children (WISC).  That is, the younger the 
child was at the time of diagnosis, the poorer the child’s performance on these nonverbal 
neurocognitive measures.  Another recent study found that children who were younger at 
diagnosis were significantly more likely to perform more poorly on the WISC 
Vocabulary and Digit Span subtests (Waber et al., 2001).  Although both the Copeland 
and Waber studies found a relation between age and neurocognitive effects, it is 
interesting to note the difference in which tasks and domains were affected.   
A second risk factor that has been identified in the literature is gender.  Although 
girls generally have a better prognosis than boys in terms of risk for relapse, they are 
generally thought to be more vulnerable to long-term neurocognitive treatment effects.   
One study found that girls treated with high-dose methotrexate scored approximately 9.3 
IQ points lower than boys receiving the same treatment (Waber et al. 1995).  In another 
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study, males scored an average of 15 Full-Scale IQ points higher than females and also 
scored significantly higher for both Verbal and Performance IQ, as well as long-term 
verbal memory and visual motor integration (Iuvone et al. 2002).  The reason for this 
significant gender difference remains unclear, however, one plausible explanation offered 
by Bleyer and colleagues (1990) is that brain development occurs at a faster rate in girls 
than boys during childhood, making girls’ brains even more vulnerable to CNS 
prophylactic treatments designed to target rapidly growing leukemic cells in the brain and 
spinal cord.  Therefore, it is possible that there is an age X gender interaction whereby 
young age at diagnosis is a factor for experiencing deficits in neurocognitive functioning 
for girls treated for ALL but not for boys.  Unfortunately, research on the potential causes 
of gender differences in neurocognitive treatment sequelae is lacking. 
Finally, it appears that length of time since the termination of ALL treatment is 
associated with greater likelihood of survivors exhibiting neurocognitive sequelae.  
Research has found that children’s performance on neurocognitive measures decreases 
over time.  Few longitudinal studies have assessed children at multiple time points 
throughout treatment and for several years following the end of treatment, but those that 
have demonstrate a rather steady decline in functioning (e.g., Rubenstein, Varni & Katz, 
1990).  It is likely that this phenomenon reflects a disruption in normative brain and 
neurocognitive development rather than an actual decline in ability (e.g., Armstrong, 
Blumberg, & Toledano, 1999). 
 
 
 
 13
Coping with Stress 
If executive functions are adversely affected in pediatric cancer survivors, one of 
the processes that may be disrupted is the ability to regulate emotions and cope with 
stress.  In the present study, coping is conceptualized according to the multidimensional 
model of responses to stress developed by Compas and colleagues (Connor-Smith et al., 
2000).  The model encompasses of both voluntary and involuntary responses to stress.  
However, this study will focus only on voluntary responses, which are thought to be self-
regulatory efforts that depend on intact higher order executive function.  Coping is 
defined as “conscious volitional efforts to regulate emotion, cognition, behavior, 
physiology, and the environment in response to stressful events or circumstances” 
(Compas et al., 2001).  This model distinguishes coping on a dimension of engagement 
with or disengagement from a stressors or one’s reactions to the stressors.  Engagement 
responses are further differentiated into primary control strategies and secondary control 
strategies, depending on the goal they aim to serve. This model has been validated in 
several independent samples of children and adolescents (e.g., Calvita & Connor-Smith, 
2004; Compas et al., 2006; Connor-Smith et al., 2000; Wadsworth et al., 2004).    
Primary control coping responses are directed toward changing the stressor itself 
or one’s emotional response to the stressor, including problem solving (e.g., I try to think 
of different ways to change the problem or fix the situation), emotional modulation (e.g., 
I keep my feelings under control when I have to, then let them out when they won’t make 
things worse), and emotional expression (e.g., I let someone or something know how I 
feel).  Secondary control coping responses are directed toward adapting to the stressor or 
ensuing emotional responses, including positive thinking (e.g., I tell myself that 
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everything will be all right), cognitive restructuring (I think about the things that I am 
learning from the situation, or something good that will come from it), acceptance (e.g., I 
realize that I just have to live with things the way they are), and distraction (e.g., I keep 
my mind off the problem by exercising, playing video games, seeing a friend, doing a 
hobby, and/or watching TV).  Both primary and secondary control coping responses have 
been associated with lower levels of emotional and behavioral problems in children and 
adolescents (e.g., Compas, Boyer et al., 2006; Connor-Smith et al., 2000; Thomsen et al., 
2002; Wadsworth & Compas, 2002). 
Disengagement coping responses are characterized by attempts to orient oneself 
away from the stressor or one’s emotional responses to the stressor.  These include 
avoidance (e.g., I try to stay away from people and things that make me feel upset or 
remind me of the problem), denial (e.g., I say to myself “This isn’t real), and wishful 
thinking (e.g., I deal with the problem by wishing it would just go away, that everything 
would work itself out).  In contrast with the engagement coping responses described 
above, which appear to be adaptive, disengagement coping responses have been 
associated with higher levels of emotional and behavioral problems (e.g., Connor-Smith 
et al., 2000).   
 
Executive Function and Coping Responses 
Coping responses are one type of a broader category of behaviors that are aimed 
at regulating emotion, cognition, behavior, and physiology (Compas et al., 2001).  As 
such, coping can be viewed as a type of executive function (Compas, 2006).  A recent 
study examined the role of one domain of executive functioning, executive inhibition, in 
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the coping responses of children with attention and externalizing problems (Copeland & 
Compas, 2007).  Executive inhibition refers to the ability to suppress dominant prepotent 
or previously reinforced responses to stimuli (Roberts & Pennington, 1996).  In this 
study, inhibitory control was measured using three standardized tests of the ability to 
delay and inhibit behavioral responses (a go-no go task, a Stroop color naming task, and a 
delay of gratification task).  Copeland and Compas (2007) found that engagement coping 
strategies, including primary control and secondary control coping, were associated with 
greater inhibitory control, while disengagement coping was associated with poorer 
inhibitory control.  Further, primary control coping responses mediated the association 
between inhibitory control and externalizing behavior problems.  That is, poor inhibitory 
control was related to more externalizing problems in part because of deficits in the use 
of primary control coping strategies.  This study provided initial evidence that executive 
inhibition is important in the development and execution of effective coping strategies.  
The proposed study seeks to build on the findings from this study by examining multiple 
domains of executive function in addition to inhibition. 
 
Executive Function, Coping, and Emotion Regulation in ALL Survivors 
Several studies have found that children with cancer report lower levels of 
emotional distress when compared to normative data (Elkin, Phipps, Mulhern, & 
Fairclough, 1997; Phipps & Srivastava, 1997) and healthy control samples (Phipps & 
Srivastava, 1997; Phipps & Steele, 2002).  Most of the patients sampled in these studies 
were still receiving treatment for ALL and therefore late effects were not assessed. 
However, a CCSS study published by Recklitis and colleagues (2006) in which a 
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heterogeneous cohort of adult childhood cancer survivors, including those treated for 
ALL, were administered the Brief Symptom Inventory-18, found that when compared to 
community participants or adult cancer patients, childhood cancer survivors reported 
significantly less psychological distress.  In contrast, another CCSS study  (Hudson et al., 
2003) examining various quality of life domains in adult survivors of childhood cancer, 
including ALL, found that survivors reported significantly more symptoms of 
psychopathology compared to their healthy adult siblings.  While the findings regarding 
late emotional and behavioral sequelae of childhood ALL treatment are mixed, there is 
good reason to believe that childhood ALL survivors are at risk for psychological 
problems. 
 Given the important role that executive function may play in the development and 
implementation of coping strategies and the link between maladaptive patterns of coping 
and emotional and behavioral problems, it is possible that the treatment-related declines 
in executive function described above lead to difficulties in generating effective coping 
strategies, which in turn leads to emotional and behavioral problems in survivors of 
childhood ALL.  The focus up until now in the field has mainly been on the implications 
of neurocognitive effects for academic achievement and work performance. However, 
there may well be an additional implication on the regulation of emotion and the ability 
to effectively cope with stress in childhood ALL survivors.   
 
Rationale for the Current Study and Hypotheses 
The current study examined executive function, coping, and emotional and 
behavioral outcomes in children and adolescents who have completed treatment for ALL 
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and a matched control sample of healthy children.  A total of seven hypotheses were 
tested.  The first three hypotheses focus on between-group comparisons in order to 
determine the extent to which childhood ALL survivors evidence impairment or 
problems compared to a healthy matched control group on the abovementioned variables: 
1) As shown in previous studies, compared to healthy controls, childhood ALL survivors 
will exhibit poorer performance on several domains of executive function, including 
working memory, mental flexibility, and behavioral inhibition. 2) Childhood ALL 
survivors will demonstrate patterns of less adaptive coping compared to healthy controls.  
That is, ALL survivors are expected to employ significantly more disengagement 
strategies and fewer primary and secondary control coping strategies.  (3) Compared to 
the healthy control sample, childhood ALL survivors will evidence higher levels of 
emotional and behavioral problems. 
The last four hypotheses focus on within-group analyses of the relations among 
the executive function, coping, and emotional variables among the survivors of ALL and 
healthy controls.  While these relations may be significant in both groups, it is expected 
that they will be stronger in the ALL group due to the predicted treatment-related 
impairment: (4) The use of primary and secondary control coping strategies will be 
positively correlated with performance on measures of executive function, whereas the 
use of disengagement coping will be negatively correlated with performance on executive 
function measures.  (5) Levels of emotional and behavioral problems will be negatively 
correlated with performance on measures of executive function. (6) Levels of emotional 
and behavioral problems will be negatively correlated with the use of primary and 
secondary control coping strategies, whereas levels of internalizing and externalizing 
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behavior problems will be positively correlated with the use of disengagement coping 
strategies. (7) Coping strategies will mediate the relation between executive function and 
emotional and behavioral problems. 
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CHAPTER II 
 
METHODS 
 
Participants 
 Participants included 30 children and adolescents between 10 and 20 years of age 
who completed treatment for ALL and 30 healthy controls matched on age, sex, and 
when possible SES.  This age range was selected because research suggests that late 
childhood and adolescence is an important period of continued myelination of the 
prefrontal cortex and development of executive functions and therefore may represent an 
age at which children are especially vulnerable to the effects of intrathecal cancer 
treatments (e.g., Klinberg et al. 1999).  Children currently within the specified age range 
who were treated for ALL at Vanderbilt Children’s Hospital were required to meet the 
following criteria to be eligible for the study: (1) completed treatment for a diagnosis of 
standard- or high-risk ALL; (2) did not receive cranial irradiation and/or bone marrow 
transplantation; (3) were in continuous first remission (i.e., no history of disease relapse).  
ALL survivors were excluded if they had a history of CNS pathology requiring radiation 
or surgery, a history of other cancer diagnoses or major medical illnesses with known 
neurocognitive sequelae (e.g., meningitis), known premorbid neurodevelopmental or 
learning problems, or a history of very low birth weight (< 1500 grams), which is also 
associated with neurocognitive impairment.   
In order to participate, healthy control participants were required to have working 
comprehension of the English language, have no history of cancer, major medical 
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illnesses, neurodevelopmental or learning disorders (including ADHD), and normal birth 
weight.     
A total of 63 children and adolescents treated for ALL with chemotherapy only 
and currently within the study age range were identified, 27 of whom could not be 
contacted as they had moved since their last follow-up appointment at Vanderbilt 
Children’s Hospital and did not have updated contact information.  One ALL survivor 
relapsed prior to recruitment and was therefore ineligible to participate.  Another ALL 
survivor had a history of bacterial meningitis, which, like ALL, is associated with 
impaired executive function (e.g., Schmidt et al., 2006), and was therefore also deemed 
ineligible to participate in the current study.  Four additional ALL survivors declined 
participation.  Therefore, of the 34 eligible ALL survivors we were able to contact, 30 
(88%) were successfully recruited for and completed the study.   
Demographics of the ALL and healthy control groups are provided in Table 1.  
There was no difference between the groups with regard to age at time of testing (t = .12, 
p = n.s.).  With regard to level of parental education, 60% of the primary caregivers in the 
ALL group and 93.4% of those in the control group had at least some college education, a 
statistically significant difference (t = -4.03, p < .01).  However, the groups did not differ 
on household income (χ = 1.15, p = n.s.).   
The mean age at time of diagnosis for the ALL group was 5.65 years (range = 1 to 
14.30 years) and ALL participants had been off treatment an average of 6.05 years (range 
= 3 months to 13.96 years).  At the time of the study assessment, the mean age of the 
ALL participants was 14.4 years and the mean age of the healthy control participants was 
14.31 years.  Eighty-six percent of the ALL group identified as White, 7% as African 
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American, and 7% as Biracial.  Ninety percent of the control group identified as White, 
with the remaining 10% identifying as Biracial.  Fifty percent of each group was female.   
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Table 1  
Demographics of ALL Survivors and Healthy Controls 
Variables        ALL           Healthy Control 
 
Sex  
     Female     15 (50%)   15 (50%) 
     Male     15 (50%)   15 (50%) 
 
Race/ethnicity (n, %) 
     White/Caucasian    26 (86.70%)   27 (90.00%) 
     Black/African American    3 (10.00%)    1 (3.33%) 
     Latino      0      1 (3.33%) 
     Biracial      1 (3.30%)    1 (3.33%) 
 
Main Caregiver (n, %) 
     Biological Mother    24 (80.00%)   26 (86.60%) 
     Biological Father     4 (13.30%)    2  (6.70%) 
     Stepmother      1 (3.30%)    2  (6.70%) 
     Grandmother     1 (3.30%)                                0 
 
Parent Education (n, %) 
     High School Graduate   21 (70.00%)    7  (23.40%) 
     College Degree      9 (30.00%)   23 (76.60%) 
 
Household Income 
     <$50,000/year         9 (30.00%)   11 (36.60%) 
     ≥$50,000/year    21 (70.00%)   19 (63.40%) 
 
Age at Testing (in years)      
     Mean (SD)     14.49 (2.88)   14.31 (2.76) 
     Range     10.11 – 20.78   10.27 – 19.64 
 
Age at ALL Diagnosis (in years) 
     Mean (SD)     5.65 (3.07)   NA 
     Range     1.00 – 14.30   NA 
 
Time Since Treatment Ended (in years) 
     Mean (SD)     6.05 (3.35)   NA 
     Range     .25 – 13.96   NA 
 
 23
Measures 
Demographic and Medical Data.  A brief intake interview was conducted with 
parents or caregivers in order to obtain basic demographic data, including relevant 
information regarding the child’s developmental, medical, and academic history.  The 
Demographic Intake Form, which was adapted from a longitudinal multicenter study 
conducted by the Children’s Oncology Group (COG ALTE02C2), was used to record the 
abovementioned information (see Appendix A).  In addition, diagnostic and treatment 
information for children previously treated for ALL was obtained by reviewing medical 
records. 
Neurocognitive Functioning.  The Wechsler Intelligence Scale for Children—
Fourth Edition (WISC-IV) or The Wechsler Adult Intelligence Scale—Third Edition 
(WAIS-III), depending on the age of the participant, was administered to measure overall 
cognitive ability, working memory, and processing speed.  Although the Working 
Memory Index (WMI), which is comprised of the Digit Span and Letter-Number 
Sequencing subtests, was the index of most interest to the study as it was one of the main 
behavioral executive function measures, the ALL and healthy control groups were also 
compared on Full Scale IQ (FSIQ) and the Processing Speed Index (PSI), and these 
variables were also examined as potential covariates.  The Wechsler intelligence scales 
demonstrate good internal consistency (r = .97) and tests-retest reliability (r = .93), and 
convergent and discriminant validity has been established. 
In addition to WMI of the WISC-IV and WAIS-III, three other subdomains of 
executive function were also measured directly using the Delis-Kaplan Executive 
Function System (D-KEFS), a comprehensive battery of tests that assesses verbal and 
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nonverbal executive functions in individuals ages 8 to 89.  The D-KEFS was standardized 
on 1,700 individuals children and adults selected to match several demographic 
characteristics of the U.S. population (Delis, Kaplan, & Kramer, 2001).  Each of the D-
KEFS tests can be used as a stand-alone instrument that can be administered individually 
or in combination with other D-KEFS tests.  In addition to higher level executive 
functions, all of the D-KEFS tests also assess component functions (i.e., fundamental 
cognitive skills on which executive functions depend) in order to better determine reasons 
for poor performance.  The D-KEFS tests yield age-corrected scaled achievement and 
process scores that have a mean of 10 and a standard deviation of 3. 
Three D-KEFS tests were administered for the current study: the Color-Word 
Interference Test, the Sorting Test, and the Tower Test.  First, the D-KEFS Color-Word 
Interference Test measures two domains of executive function: behavioral inhibition and 
cognitive flexibility.  This test includes two conditions assessing the component functions 
of basic naming of color patches and basic reading of words denoting colors, which 
presumably are skills required to perform the higher-level tasks presented in the last two 
conditions.  The third condition is the traditional Stroop interference task, in which the 
examinee is required to inhibit the prepotent response of reading the words denoting 
colors in order to name the dissonant ink colors in which the words are printed.  Finally, 
the fourth condition requires the examinee to switch back and forth between naming the 
dissonant ink colors and reading the conflicting words.  Normative data are provided for 
completion times for each of the four conditions and contrast measures for determining 
for parceling scores on component function conditions from scores on higher-level tasks.  
For the current study, only scores for the third condition, the Stroop color-word 
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interference task that measures behavioral inhibition, were used in the statistical analyses, 
as it most directly measures this particular domain of executive function.   
The D-KEFS Sorting Test measures verbal and nonverbal problem-solving, 
conceptual reasoning, and the initiation of problem-solving behavior. The test consists of 
two testing conditions: Free Sorting and Sort Recognition.  For the first condition, 
examinees are presented with cards displaying perceptual features and printed words and 
are required to sort them into groups according to as many different concepts or rules 
they can think of.  In the second condition, the examiner sorts the same sets of cards 
according to eight possible target sorts and asks the examinee to identify and describe the 
rules or concepts by which the cards were sorted.  Normative data are provided for 
number of confirmed correct sorts and descriptions for the Free Sorting Condition and 
sort recognition descriptions for the second condition.  Additionally, a combined 
description score is calculated across both conditions, as well as a contrast score in 
descriptions between the two conditions.  For the current study, only the Free Sort 
description scores were included in the analyses because it measures the executive 
function domain of cognitive flexibility and set-shifting ability. 
Finally, the D-KEFS Tower Test measures several domains of executive function, 
including spatial planning, rule learning, inhibition of impulsive responding, inhibition of 
perseverative responding, and establishing and maintaining an instructional set.  The test 
requires the examinee to move up to five disks that vary in size on a board with three 
pegs in order to construct increasingly more complex “towers” in the fewest number of 
moves possible.  In order to construct the target tower, the examinee must follow two 
rules: (1) only move one disk at a time and (2) never place a larger disk over a smaller 
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one.  The Total Achievement score, which is based on the number of moves it took the 
participant to complete the towers, was used in the statistical analyses.   
In addition to these direct behavioral measures, executive function was also 
assessed through parent report.  Participants’ primary caregivers completed the Brief 
Rating Inventory of Executive Function (BRIEF; Gioia, Isquith, Guy, & Kenworthy, 
2000), a questionnaire that allows parents to rate their children on a list of 86 problem 
behaviors reflecting various domains of executive function over the past six months 
according to a three-point scale: N if the behavior is never a problem, S if the behavior is 
sometimes a problems, O if the behavior is often a problem, scored as 1, 2, or 3, 
respectively.  The BRIEF yields scale scores (raw scores and T scores) for eight different 
domains of executive function: Inhibit, Shift, Emotional Control, Initiate, Working 
Memory, Plan/Organize, Organizations of Materials, and Monitor.  In addition, three 
broader index scores confirmed by factor analyses are generated (Gioia, Isquith, Retzlaff, 
& Espy, 2002).  The Behavioral Regulation Index (BRI) is obtained by summing the 
scores for the Inhibit, Shift, and Emotional Control scales.  The Metacognition Index 
(MI) is obtained by summing the scores for Initiate, Working Memory, Plan/Organize, 
Organization of Materials, and Monitor.  Finally, the Global Executive Composite 
(GEC), which reflects the child’s overall executive functioning across all of the domains 
measured, is obtained by summing the BRI and MI indexes.  The BRIEF was 
standardized on 1,419 parents with demographic compositions representative of the 1999 
US census.  It has high internal consistency (alphas = .80-.98) and test-retest reliability (r 
= .82), and convergent validity has been established with other measures of executive 
function (Gioia et al., 2000).  It should also be noted that for the current study, the BRIEF 
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was reverse scored to reflect more problems, which facilitated its interpretation and 
comparison with the other study measures in the statistical analyses. 
For the purpose of this study, only the Working Memory, Inhibit, Shift, and 
Monitor subscales of the BRIEF were used, as they were deemed to most closely measure 
the executive functions behaviorally assessed with the WISC/WAIS WMI (BRIEF 
Working Memory), D-KEFS Color-Word (BRIEF Inhibit)—both are measures of 
behavioral inhibition, D-KEFS Sorting Test (BRIEF Shift)—both are measures of 
cognitive flexibility, and D-KEFS Tower (BRIEF Monitor)—both reflect the ability to 
self-monitor one’s behavior. 
Coping.  The Responses to Stress Questionnaire (RSQ), both self- and parent-
report versions, was administered to assess the coping responses of ALL and healthy 
control participants (Connor-Smith et al., 2000).  It has been adapted to specifically target 
coping responses related to social stress, a domain in which both ALL survivors and 
controls are likely to have experienced a sufficient base rate of stressors to complete the 
measure.  The RSQ measures both voluntary and involuntary responses to stress; 
however, the current study focuses solely on the three voluntary coping domains: Primary 
Control coping (problem solving, emotional modulation, emotional expression), 
Secondary Control coping (acceptance, cognitive restructuring, positive thinking, 
distraction), and Disengagement coping (avoidance, denial, wishful thinking).  With 
regard to its reliability and validity, the RSQ has been shown to have good test-retest 
reliability (alphas ranged from .69 to .81) and internal consistency (alphas ranged from 
.67 to .92), and convergent and discriminant validity has been established.   
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Emotional and Behavioral Problems.  The Child Behavior Checklist (CBCL; 
Achenbach, 1991) was administered to all parents or caregivers in order to determine 
their perceptions of the children’s emotional and behavioral functioning and 
competencies over the past six months.  Similarly, the Youth Self-Report (YSR; 
Achenbach, 1991) was administered to all children participating in the study in order to 
determine their perceptions of their own functioning.  Both the CBCL and the YSR 
require respondents to report the frequency of 112 problem behaviors or symptoms on a 
three-point scale: 0 = Not True; 1 = Somewhat or Sometimes True; 2 = Very True or 
Often True.  Both questionnaires yield raw and T scores indicating children’s level of 
overall internalizing and externalizing problems and more specific syndromes, including 
Anxious/Depressed, Withdrawn/Depressed, Somatic Complaints, Social Problems, 
Thought Problems, Attention Problems, Rule-Breaking Behavior, and Aggressive 
Behavior.  The Achenbach System of Empirically-Based Assessment (ASEBA), which 
includes the CBCL and YSR, demonstrates strong test-retest reliability (.75-.95), as well 
as good convergent and discriminant validity.  For the purpose of this study, only 
internalizing and externalizing problems will be included in the analyses.   
 
Procedure 
The parents or caregivers of ALL survivors were sent a letter from a physician 
who was not involved in the child’s clinical care inviting them to participate in the 
proposed research study (see Appendix B). The physician then placed a follow-up call to 
the family approximately one week after the letter was sent to answer any questions about 
the study and to gauge the family’s interested in participating.  If families expressed 
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interest, an appointment was scheduled for them to come to the Pediatric Hematology/ 
Oncology clinic for study assessment. 
Upon arriving for the session, informed consent and assent was obtained from 
participants and parents.  After answering any questions, the examiner asked interested 
parents and patients to sign the Consent and Assent Forms, respectively (see Appendix C 
and D).  At this time, the examiner also asked ALL participants and parents to generate a 
list of peers who were of the same age and sex in order to identify healthy controls for the 
study.  ALL participants were shown copies of three different versions of a letter that 
could be sent to potential healthy controls inviting them to participate in the study (see 
Appendix E).  The first letter would be sent to peer nominees if the ALL participant 
wanted to be personally identified as a participant in this study and to disclose his or her 
status as a leukemia survivor.  The second letter would be sent if the ALL participant 
chose to be identified but did not wish to reveal that he or she was treated for leukemia.  
Finally, the third letter would be sent if the ALL participant chose to remain completely 
anonymous.  ALL participants and their parents were given the opportunity to decline 
this method of identifying controls.  Only five healthy controls were identified by this 
method, as the remaining ALL participants declined to nominate peers, usually because 
they assumed none of their friends would be interested or have time to participate.  
Therefore, healthy controls were also recruited through Vanderbilt University Medical 
Center Clinical Trials Office.  Specifically, a mass email was sent to staff and faculty at 
the Vanderbilt Medical Center advertising for a study examining neurocognitive 
development in children and adolescence (see Appendix F).  The email distribution list 
includes all staff and faculty who have email addresses, ranging from clerical staff to 
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medical professional staff and faculty.  Interested individuals who responded to the email 
were administered a screening interview to determine whether the child met criteria and 
also whether the child was an age and sex match to an ALL participant who already 
enrolled in the study.  Excluding the identification of peers for potential recruitment, the 
procedure for obtaining consent and assent and data collection was the same for healthy 
controls participating in this study (see Appendices G and H for healthy control consent 
and assent forms). 
 Next, the examiner conducted a brief demographic intake interview with the 
parent and asked the parent to complete the CBCL, BRIEF, and the parent-report version 
of the RSQ in a separate room.  The examiner then administered the YSR and the self-
report version of the RSQ to the child.  Once they completed the questionnaires, children 
were then administered the WISC-IV or WAIS-III, depending on the participant’s age, 
and the D-KEFS tests mentioned above.  The average appointment lasted approximately 
three hours.  Following testing, completed questionnaires were collected from the parent, 
parents and children were debriefed, and each received an honorarium of $25, and an 
additional $10 to compensate for any travel costs.    
 
Statistical Analyses 
 Means and standard deviations were calculated for neurocognitive, coping, and 
emotional and behavioral outcomes, and between-group differences were examined for 
each of these variables using independent samples t-tests.  In addition, effect sizes 
(Hedges gs) were calculated to determine the magnitude of effects comparing the ALL 
group to the healthy control group and both groups to normative data.  Hedges g 
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represents the number of standard deviations the ALL group means on a given 
neurocognitive test differ from the mean of the normative or comparison group.  Positive 
effect sizes indicate that the ALL group performed better than the normative or control 
sample.  Conversely, negative values indicate that the ALL group performed more 
poorly.  According to Cohen (1988), effect sizes less than .2 indicate negligible effects, 
those between .2 and .5 indicate small effects, those between .5 and .8 indicate medium 
effects, and those greater than .8 are considered large effects.   
Pearson product-moment correlation coefficients for relations between executive 
function, coping, and emotional and behavioral outcome variables were conducted 
separately for the self- and parent-reported data in each group.     
Hierarchical linear multiple regression analyses were conducted to predict 
internalizing and externalizing behavior problems from each executive function and 
coping factor.  More specifically, coping was tested as a mediator of the relation between 
executive function and emotional problems following the methodology discussed by 
Baron and Kenney (1986).  In accordance with this method, three criteria must be met in 
order to test for mediation: (1) executive function measures significantly correlated with 
internalizing and externalizing behavior problems; (2) coping variables significantly 
correlated with internalizing and externalizing behavior problems; (3) executive function 
measures significantly correlated the coping variables.  When all three criteria were met 
for a set of independent and dependent variables, a regression equation was conducted 
entering the executive function variable in the first step and entering the coping variable 
in the second step in order to test for mediation.  Evidence for a fully mediated model 
occurs when executive function significantly predicts emotional problems in the first step 
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but is no longer significant once the coping variable is added in the second step.  
Evidence for a partially mediated model occurs when both the executive function and 
coping variables remain significant predictors of emotional problems in the second step.  
When either form of mediation was demonstrated through these regression analyses, a 
Sobel test was performed in order to test the indirect effect of the independent variable on 
the dependent variable through the mediator using the following equation (Sobel, 1982): 
                                                         ab 
z   =           √b2sa2 + a2sb2 + sa2sb2
In Sobel’s formula, the path from the independent variable (executive function) to 
the mediator (coping) is denoted as “a” and the standard error as “sa”.  The path from the 
mediator (coping) to the dependent variable (emotional problem) is denoted by “b” and 
its standard error is “sb”.   
 
Statistical Power 
 Given the results from a recently published meta-analysis, which demonstrated 
mostly small to medium effect sizes when comparing ALL and control groups on various 
neurocognitive functions, similar effects were expected to be found in the current study 
(Campbell et al., in press).  However, power analyses indicated that with the current 
sample of 30 participants in each group, the power to detect small effects (d ≥ .2) was 
.19, medium effects (d ≥ .5) was .61, and large effects (d ≥ .8) was .92.  In order to 
compensate for lower power, effect sizes were conducted and presented in this paper to 
better display between-group differences, as it was expected that some between-group 
results would not be statistically significant.  With regard to within-group relations 
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among variables, the power to detect correlations of .40 or greater at the p < .05 level of 
significance was adequate (.72).   
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CHAPTER III 
 
 RESULTS 
 
Descriptive Statistics 
 Means and standard deviations for executive function, coping, and emotional and 
behavioral problems are reported in Table 2.  With regard to WISC/WAIS scores, FSIQ 
for the ALL group fell within the Average range and were in the High Average range for 
the healthy control group.  WMI and PSI scores fell within the Average range for both 
the ALL and healthy control groups.  Likewise, all D-KEFS and BRIEF scores for both 
groups fell within the average range (see Table 2 for mean scores and standard 
deviations).   
 Demographic, medical, and cognitive variables were examined separately for 
each group to determine if they were significantly correlated with the dependent variables 
(internalizing and externalizing behavior problems) and should therefore be controlled for 
in the regression analyses.  Sex and age at the time of the evaluation were examined in 
both groups, and age at time of diagnosis and number of years since treatment were also 
examined in the ALL group.  None of these variables were significantly correlated with 
CBCL and YSR internalizing or externalizing symptoms in either group.   
Because processing speed was expected to be related to the key variables, as 
impairment of this neurocognitive domain is common in ALL survivors, correlational 
analyses were also performed between WISC/WAIS FSIQ, WISC/WAIS PSI and the 
dependent variables, internalizing and externalizing behavior problems.  Again, no 
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significant correlations were found between FSIQ or PSI and the behavioral outcome 
variables for either group.   
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Table 2 
Mean Scaled Scores and Standard Deviations for FSIQ and the Executive Function Variables 
 
Overall Cognitive Ability and  
Executive Function 
ALL Group 
Mean (SD)  
 
Healthy Control Group 
Mean (SD) 
WISC-IV/WAIS-III FSIQ 100.89 (15.37) 113.33 (11.16) 
WISC-IV/WAIS-III PSI 93.28 (14.68) 102.96 (15.30) 
WISC-IV/WAIS-III WMI 97.27 (16.32) 106.38 (13.01) 
D-KEFS Color-Word Interference 10.57 (2.08) 10.40 (2.27) 
D-KEFS Sorting Test  10.60 (3.04) 11.83 (2.07) 
D-KEFS Tower Test  10.34 (2.27) 10.57 (2.45) 
BRIEF Working Memory 51.75 (13.37) 46.81 (7.82) 
BRIEF Inhibit 47.82 (13.00) 46.74 (6.30) 
BRIEF Shift 52.14 (18.32) 47.81 (8.29) 
BRIEF Monitor 51.18 (15.62) 48.30 (9.37) 
RSQ scales  Self / Parent Self / Parent 
Primary Control Engagement .20 (.04) / .22 (.05) .20 (.04) / .23 (.04) 
Secondary Control Engagement .26 (.05) / .25 (.05) .27 (.04) / .26 (.05) 
Disengagement .14 (.03) / .15 (.03) .15 (.03) / .15 (.03) 
Emotional/Behavioral Outcomes    YSR/CBCL    YSR/CBCL 
Internalizing Problems 52.30 (10.29) / 51.39 (12.49) 51.63 (7.80) / 53.31 (9.79) 
 
Externalizing Problems 49.60 (9.15) / 50.39 (9.85) 51.73 (7.33) / 50.14 (8.79) 
 
Note: Higher scores on the BRIEF indicate poorer performance 
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Cross-informant correlations 
 Cross-informant (i.e., parents and children) analyses were conducted by 
performing Pearson product-moment correlations among the self-reported and parent-
reported coping and emotional problem variables independently for each group. 
ALL Group.  Self-reported primary control coping was not significantly 
correlated with parent-reported primary control coping or CBCL internalizing and 
externalizing problems, nor was it correlated with YSR internalizing or externalizing 
problems. Self-reported secondary control coping was significantly and negatively 
correlated with both CBCL and YSR internalizing and externalizing problems.  It was not 
correlated with parent-reported secondary control coping but was positively correlated 
with parent-reported primary control coping.  Self-reported disengagement coping was 
significantly and negatively correlated with parent-reported primary control coping but 
was not significantly correlated with parent-reported disengagement coping or CBCL and 
YSR internalizing and externalizing problems.   
Parent-reported primary control coping was significantly and negatively 
correlated with CBCL internalizing and externalizing problems but not with the YSR.  
The correlation between parent-reported secondary control coping and YSR externalizing 
problems approached significance.  Secondary control coping was not significantly 
correlated with YSR internalizing problems but did negatively correlated with CBCL 
internalizing and externalizing problems.  Finally, parent-reported disengagement coping 
significantly correlated only with CBCL internalizing problems and approached 
significantly with externalizing problems. 
 38
Healthy Control Group.  Self-reported primary control coping and disengagement 
coping were not significantly correlated with any of the parent-reported coping variables, 
nor were they correlated with CBCL or YSR internalizing and externalizing problems.  
However, self-reported secondary control coping was negatively correlated with parent-
reported disengagement coping and YSR internalizing problems. 
 The correlation between parent-reported primary control coping and CBCL 
internalizing approached significance.  It was not correlated with either of the YSR 
variables.  Parent-reported secondary control coping was not correlated with CBCL or 
YSR variables.  Finally, parent-reported disengagement coping was positively correlated 
with YSR internalizing problems only. 
 
Hypotheses 
 The rest of the results section is organized in correspondence with each of the 
seven hypothesis outlined above.   
Hypothesis 1.  First, it was predicted that compared to healthy controls, childhood 
ALL survivors would exhibit poorer performance on several domains of executive 
function, including working memory, mental flexibility, and behavioral inhibition.  
Comparisons between the ALL and healthy control groups were made using independent 
samples t tests.  With regard to the executive function measures, significant differences 
were found on the WISC-IV/WAIS III WMI (t = -2.15, p < .05), while the BRIEF 
Working Memory Scale and the D-KEFS Sorting Test approached significance (t = -1.89, 
p = .06; t = -1.86, p = .07, respectively.  In addition, the groups significantly differed on 
WISC/WAIS FSIQ (t = -3.37, p < .01) and WISC/WAIS PSI (t = -2.50, p < .05).  These 
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group differences were in the predicted direction, with the ALL group evincing poorer 
performance than the healthy control group.  No significant between-group differences 
were detected for any of the other executive function measures, nor the coping or 
emotional outcome measures.      
Because the two groups differed significantly with regard to parent education, 
with more healthy control parents having more college education that ALL parents (t = -
4.03, p < .01), and parent education is a significant predictor of intelligence in children, 
analyses of covariance were also run comparing the groups on FSIQ, PSI, and the 
executive function measures with parent education entered as a covariate.  The following 
between-group differences still remained significant or approached significance even 
after accounting for parent education: WISC/WAIS FSIQ [F (2, 55) = 6.21, p < .05]; 
WISC/WAIS WMI [F (2, 55) = 3.07, p = .07); BRIEF Working Memory [F (2, 55) = 
3.09, p = .07).  The between-group differences between the D-KEFS Sorting Test and 
WISC/WAIS PSI no longer approached significance.  It should be noted, however, that 
parent education did not account for a statistically significant amount of variance in any 
of these analyses.    
 In addition to t-tests, effect sizes (Hedges gs) were calculated to determine the 
magnitude of effects comparing the ALL group to the healthy control group and also 
comparing both groups to normative samples (see Table 3).  Hedges g represents the 
number of standard deviations the ALL group means on a given neurocognitive test differ 
from the mean of the normative or comparison group.  Positive effect sizes indicate that 
the ALL group performed better than the normative or control sample.  Conversely, 
negative values indicate that the ALL group performed more poorly.   
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Table 3 
Effect sizes (Hedge’s gs) Comparing ALL Sample to Normative Data and a Matched 
Healthy Control Sample 
 
 
 
Neurocognitive Measure 
 
ALL vs 
Normative 
Data 
 
 
Healthy 
Control vs 
Normative 
Data 
 
ALL vs 
Healthy 
Control 
 
WISC/WAIS FSIQ +.06 +1.02 -.94 
WISC/WAIS PSI -.45 +.20 -.62 
WISC/WAIS WMI -.17 +.46 -.62 
D-KEFS Color-Word Inhibit +.22 +.15 -.23 
D-KEFS Sorting Test +.20 +.72 -.48 
D-KEFS Tower Test  +.13 +.21 -.10 
BRIEF Working Memory -.15 +.36 -.53 
BRIEF Inhibit +.19 +.40 -.06 
BRIEF Shift -.15 +.24 -.30 
BRIEF Monitor -.01 +.18 -.22 
 
Note: Negative signs indicate that the ALL group performed more poorly on the measure 
compared with the normative or comparison group; Positive signs indicate that the groups 
performed better than the control group or that the ALL group performed better than the 
healthy control group. 
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 All effect sizes comparing the ALL group to the control group on the executive 
function measures were in the negative (expected) direction indicating poorer 
functioning.  The effects comparing the groups on executive function measures ranged 
from negligible to medium (g = -.06 to -.62; see Table 3).  Medium effects were found for 
WISC-IV/WAIS-III WMI (g = -.62) and BRIEF Working Memory (g = -.53).  Small 
effects were found for the D-KEFS Sorting Test (g = -.48), D-KEFS Color-Word 
Inhibition (g = -.23), BRIEF Shift (g = -.30), and BRIEF Monitor (g = -.22).  In addition, 
a large effect was found for WISC/WAIS FSIQ (g = -.94), and a medium effect was 
found for WISC/WAIS PSI (g = -.62). 
 When the ALL group was compared with normative data on the WISC/WAIS and 
D-KEFS, only one small negative effect was found: WISC/WAIS PSI (g = -.45).  All 
other effects were either negligible or small positive effects, which were unexpected (see 
Table 3).  When comparing the healthy control group to normative data, all effects were 
in the positive direction, ranging from negligible to large (+.15 to +1.02), with FSIQ 
being the largest.   
Hypothesis 2.  The second hypothesis predicted that childhood ALL survivors 
would demonstrate patterns of less adaptive coping compared to healthy controls.  That 
is, ALL survivors were expected to employ significantly more disengagement strategies 
and fewer primary and secondary control coping strategies.  No significant differences 
were found between the two groups with regard to self- or parent-reported coping 
strategies.  Both raw scores (the number of coping responses endorsed for each domain of 
coping) and proportion scores (raw scores divided by the overall number of coping 
responses endorsed) were examined. 
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 Effect sizes (Hedges’ gs) were also computed to compare the ALL and healthy 
control groups with regard to coping strategies.  Small but non-significant effects were 
found for both self-reported secondary control coping (g = -.36) and parent-reported 
secondary control coping (g = -.20), with ALL patients and their parents consistently 
endorsing a lower proportion of secondary control strategies than did healthy control 
participants and their parents.  Effects for primary control coping and disengagement 
coping were negligible.    
Hypothesis 3.  The third hypothesis predicted that compared to the healthy control 
sample, childhood ALL survivors will evidence higher levels of internalizing problems.  
However, no significant between-group differences were found with regard to the CBCL or YSR 
variables.  Also, contrary to the hypothesis, the effect size for the CBCL Internalizing Scale, 
although non-significant, was small and in the positive direction (g = +.23), indicating that 
healthy control parents endorsed greater internalizing symptoms than did the ALL parents.  On 
the other hand, the YSR Internalizing effect size was negligible and in the negative direction (g = 
-.09).  The Externalizing scales on both the CBCL and YSR were negligible.  When the CBCL 
syndrome scales were examined, small but non-significant negative effects were found for the 
Social Problems (g = -.45), Attention Problems (g = -.41), and Rule-Breaking (g = -.22) scales, 
indicating that ALL parents endorsed more symptoms on these scales than did healthy control 
parents.  Surprisingly, a small (but non-significant) positive effect was found for the Somatic 
Problems scale (g = +.30), showing that healthy control parents reported greater symptoms in 
their children than parents of ALL survivors.   
With regard to the YSR syndrome scales, small non-significant negative effects 
were found for the Anxious/Depressed (g = -.24) and Somatic Problems (g = -.36) scales, 
indicating that ALL participants endorsed more symptoms on these scales than did 
healthy control participants.  Small (but on-significant) positive effects were found for 
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the following YSR syndrome scales: Withdrawn/Depressed (g = +.21), Social Problems 
(g = +.28), and Aggressive Problems (g = +.36), indicating that healthy control 
participants endorsed more symptoms on these scales than did ALL participants.   
Hypothesis 4.  The fourth hypothesis predicted that the use of primary and 
secondary control coping strategies would be positively correlated with performance on 
measures of executive function, whereas the use of disengagement coping would be 
negatively correlated with performance on executive function measures.  These 
correlations were expected to be stronger for the ALL group than the healthy control 
group.   
 
ALL Group  
 All correlations among the executive function and coping measures for the ALL 
group that reached or approached statistical significance were in the expected directions.  
First, correlations among the various executive function measures and self-reported 
coping variables were examined (See Table 4).  Consistent with the hypothesis, self-
reported secondary control coping was positively correlated with BRIEF Working 
Memory (r = .55, p < .01), BRIEF Shift (r = .38, p < .05), and BRIEF Monitor (r = .52, p 
< .01).  The correlation between BRIEF Inhibit and self-reported secondary control 
coping approached significance (r = .32, p = .07).  Also in accordance with the 
hypothesis, self-reported disengagement coping was negatively correlated with the 
WISC/WAIS WMI  (r = -.44, p < .05), D-KEFS Tower Test (r = -.42, p < .05), BRIEF 
Working Memory (r = -.47, p < .05), and BRIEF Monitor (r = -.41, p < .05).  The 
correlation between BRIEF Inhibit and self-reported disengagement coping approached 
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significance (r = -.35, p = .06).  None of the correlations among the executive function 
measures and self-reported primary control coping were significant. 
 Next, the correlations among the executive function measures and parent-reported 
coping variables were examined (See Table 5).  As expected, parent-reported primary 
control coping was positively correlated with WAIS/WISC WMI (r = .43, p < .05), D-
KEFS Sorting Test (r = .52, p < .01), BRIEF Working Memory (r = .69, p < .01), BRIEF 
Shift (r = .54, p < .01), BRIEF Inhibit (r = .66, p < .01), and BRIEF Monitor (r = .61, p < 
.01).  Also consistent with the hypothesis, parent-reported secondary control coping was 
positively correlated with BRIEF Working Memory (r = .54, p < .01), BRIEF Shift (r = 
.45, p < .05), and BRIEF Monitor (r = .49, p < .01).  Also as predicted, parent-reported 
disengagement coping was negatively correlated with BRIEF Working Memory (r = -.50, 
p < .01), BRIEF Inhibit (r = -.52, p < .01), and BRIEF Monitor (r = -.47, p < .05).  The 
negative correlations between parent-reported disengagement coping and WAIS/WISC 
WMI and BRIEF Shift approached significance (r = -.36, p = .06 for both).   
 
Healthy Control Group 
 No significant correlations were found among the executive function and self-
reported coping variables for the healthy control group (See Table 4).  However, several 
significant correlations, all in the expected directions, were found for parent-reported 
coping variables (See Table 5).  Parent-reported primary control coping was positively 
correlated with WISC/WAIS WMI (r = .41, p < .05) and BRIEF Monitor (r = .38, p < 
.05).  In addition, the correlation between parent-reported primary control coping and 
BRIEF Shift approached significance (r = .34, p = .07).  Also, a negative correlation 
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between parent-reported disengagement coping and BRIEF Inhibit approached 
significance (r = -.33, p = .08).    
Table 4 
Correlations Among Executive Function, Self-Reported Coping, and Self-Reported Emotional and Behavioral Problems  
    1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13.       
 
1. WISC/WAIS WMI                           -.20          -.08          .43*          -.27        -.01           -.16 .35+ .06           .14          .26 -.26 -.17 
2. D-KEFS Sorting                               .47**              -.38*        -.10 .02         -.25 .21 .00          -.12 .14 .00 -.16 -.09   
3. D-KEFS C-W Inhibit                       .35+        -.21               .17            -.19 .17          -.32 .05          -.03 .02 .10 -.14 -.16 
4. D-KEFS Tower                               .32          .35+         .51**                -.35+       -.10          -.16 .12  .25 .15 .04 -.28 -.24 
5. BRIEF Working Memory                 .25         .49**        .04           .08  .28 .41* .44*  .05 .06         -.14 -.01 -.24 
6. BRIEF Shift                .20          .46**        .00           .18           .61**         .13 .34+ -.16         -.02           .07  .16 -.38* 
7. BRIEF Inhibit                .41*        .61**        .18          .18            .74**        .38*  .35+  .00 -.10         -.07 -.20 -.09 
8. BRIEF Monitor                                 .26          .54**       .02          .04             .88**       .70**       .71**    .11 -.10         -.24  .06   .02 
9. Primary Control Coping                .30           .20          .27          .22             .14            .18          .11          .22  -.01         -.63** -.26 -.33+ 
10. Secondary Control Coping             .09           .22          .12          .09              .55**       .38*        .32+        .52**        .15                -.07           -.42* -.23 
11. Disengagement Coping                 -.44*        -.30         .16          -.42*          -.47*         -.20        -.35+      -.38*         -.41*         -.62**  -.01  .09 
12. Internalizing Problems               .11          -.08        -.08          -.09            -.15           -.16        -.04        -.33+          .01           -.64**        .20   .54** 
13. Externalizing Problems              -.35+         .11        -.49**      -.26            -.21           -.09          .04       -.26             .04          -.51**         .13          .69** 
Note: Healthy control correlations are on the top right 
         BRIEF scales were reverse scored such that lower scores rather than higher scores indicate poorer functioning; + p < .10 (approaching significance), * p <. 05, ** p < .01 
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2. D-KEFS Sorting                               .47**              -.38*        -.10 .02         -.25 .21 .00          -.01 .04 .07  .22  .27   
9. Primary Control Coping                .43*        .52**        .03         -.03            .69**       .54**        .66**       .61**  -.10 -.66**      -.35+        -.18   
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Table 5 
Correlations Among Executive Function, Parent-Reported Coping, and Parent-Reported Emotional and Behavioral Problems  
    1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13.       
          BRIEF scales were reverse scored such that lower scores rather than higher scores indicate poorer functioning; + p < .10 (approaching significance), * p <. 05, ** p < .01 
7. BRIEF Inhibit                .41*        .61**        .18          .18            .74**        .38*  .35+ .08 .06 -.33+ .04 -.26 
1. WISC/WAIS WMI                           -.20          -.08          .43*          -.27        -.01           -.16 .35+ .41* .18 .08 -.19 -.04 
5. BRIEF Working Memory                 .25         .49**        .04           .08  .28 .41* .44* .31 .29 -.01 -.09 -.32          
3. D-KEFS C-W Inhibit                       .35+        -.21               .17            -.19 .17          -.32 .05           .27 -.31 -.08 -.29 -.05 
6. BRIEF Shift                .20          .46**        .00           .18           .61**         .13 .34+ .34+ -.10 -.27 -.52** -.44* 
12. Internalizing Problems              -.25         -.42*        -.21          .15          -.68**       -.76**      -.42*         -.78**      -.68**       -.65**      .66**                        .49** 
8. BRIEF Monitor                                 .26          .54**       .02          .04             .88**       .70**       .71**    .38* -.10 -.21 -.27 -.54** 
10. Secondary Control Coping             .04          .27            .17          .27            .54**        .45*         .30            .49**        .48**                      -.14          -.11          -.10 
11. Disengagement Coping                 -.36+       -.29          -.09          .20           -.50**      -.36+        -.52**       -.47*        -.72**       -.63**                      .32+         .09 
4. D-KEFS Tower                               .32          .35+         .51**                -.35+       -.10          -.16 .12          -.13 .11 -.04 -.08 .11 
13. Externalizing Problems               .01         -.45*        -.14          .13           -.80**      -.66**      -.62**       -.76**      -.60**       -.66**      .34+          .64** 
Note:  Healthy control correlations are on the top right 
 
 
Between-Group Comparison of Correlations 
It was predicted that associations among the executive function and coping 
variables would be stronger for the ALL group than for the control group.  In order to 
compare correlations that were found to be significant or approaching significance among 
executive function and coping variables for the ALL and healthy control groups, Fisher’s 
z-tests were computed using the following formula:   
 
z = .5[Ln (1+r1) – Ln (1-r1)] - .5[Ln (1+r2) – Ln (1-r2)]
                                   (1/n1 – 3) + (1/n2)1/2
Only four sets of correlations were statistically significant or approached 
significance in the correlation matrices of both groups: WISC/WAIS WMI and Parent-
Reported Primary Control Coping; BRIEF Monitor and Parent-Reported Primary Control 
Coping; BRIEF Shift and Parent-Reported Primary Control Coping; and BRIEF 
Inhibition and Parent-Reported Disengagement Coping.  Contrary to the hypothesis, no 
between-groups differences were found regarding the strength of these relations (z = .09, 
z = 1.13, z = .92, and z = -.86, respectively).   
However, it should also be noted that out of 128 possible correlations among the 
various executive function variables, self- and parent-reported coping variables, and self- 
and parent-reported emotional/ behavioral outcome variables for each group, 65 
correlations (50.78%) were significant or approached significance for the ALL group, 
compared to only 17 (13.28%) for the healthy control group, and many of the differences 
between these correlations are statistically significant.     
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Hypothesis 5.  The fifth hypothesis predicted that levels of internalizing and 
externalizing behavior problems would be negatively correlated with performance on 
measures of executive function.   
 
ALL Group 
All correlations among the executive function and emotional outcome measures 
for the ALL group that reached or approached statistical significance were in the 
expected directions.  First, correlations among the various executive function measures 
and self-reported internalizing and externalizing behaviors were examined (See Table 4).  
Consistent with the hypothesis, a negative correlation between YSR internalizing 
behavior and BRIEF Monitor approached significance (r = -.33, p = .08).  In addition, a 
significant negative correlation was found between YSR externalizing behavior and D-
KEFS Color-Word Inhibition (r = -.49, p < .01).  The correlation between YSR 
externalizing behavior and WISC/WAIS WMI also approached significance (r = -.35, p = 
.06).   
Next, the correlations among the executive function measures and parent-reported 
emotional outcome measures were examined (See Table 5).  As expected, CBCL 
internalizing behavior was negatively correlated with D-KEFS Sorting Test (r = -.42, p < 
.05), BRIEF Working Memory (r = -68, p < .01), BRIEF Shift (r = -.76, p < .01), BRIEF 
Inhibit (r = -.42, p < .05), and BRIEF Monitor (r = -.78, p < .01).  Likewise, CBCL 
externalizing behavior was also negatively correlated with the same executive function 
measures: D-KEFS Sorting Test (r = -.45, p < .05), BRIEF Working Memory (r = -.80, p 
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< .01), BRIEF Shift (r = -.66, p < .01), BRIEF Inhibit (r = -.62, p < .01), and BRIEF 
Monitor (r = -.76, p < .01). 
 
Healthy Control Group 
 Self-reported externalizing behavior problems on the YSR were negatively 
correlated with BRIEF Shift (r = -.38, p < .05; See Table 4).  No other correlations among 
the self-reported emotional outcome variables and executive function measures were 
found for the healthy control group.  With regard to parent-reported emotional variables, 
a significant negative correlation was detected between CBCL Internalizing Behavior and 
BRIEF Shift (r = -.52, p < .01; See Table 5).  In addition, negative correlations were 
found between CBCL Externalizing Behavior and BRIEF Shift (r = -.44, p < .01) and 
BRIEF Monitory (r = -.54, p < .01).   
 
Between-Group Comparison of Correlations 
Again, it was predicted that associations among the executive function and 
emotional outcome variables would be stronger for the ALL group than for the control 
group.  Between-group comparisons of significant correlations were conducted using 
Fisher’s z-tests.  Three sets of correlations were statistically significant or approached 
significance in both groups: BRIEF Shift and CBCL Internalizing Behavior, BRIEF Shift 
and CBCL Externalizing Behavior, and BRIEF Monitor and CBCL Externalizing 
Behavior.  No between-groups differences were found regarding the strength of these 
relations (z = -1.54, z = -1.18, and z = -1.44, respectively).   
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Hypothesis 6.  The sixth hypothesis predicted that levels of internalizing and 
externalizing behavior problems would be negatively correlated with the use of primary 
and secondary control coping strategies, whereas levels of internalizing and externalizing 
behavior problems would be positively correlated with the use of disengagement coping 
strategies. 
 
ALL Group 
All correlations among the coping and emotional variables that were statistically 
significant or approached significance were in the expected directions.  Regarding self-
reported coping and emotional outcomes, secondary control coping was negatively 
correlated with YSR internalizing problems (r = -.64, p < .01) and externalizing problems 
(r = -.51, p < .01; See Table 4).  Self-reported primary control and disengagement coping 
were not significantly correlated with either YSR variable.   
With regard to cross-informant analyses, as mentioned above, self-reported 
secondary control coping was significantly and negatively correlated with CBCL 
internalizing and externalizing problems (r = -.46, p < .05 for both; See Table 6).  
However, neither self-reported primary control coping nor disengagement coping were 
correlated with either CBCL variable.   
 With regard to parent-report, both primary and secondary control coping were 
negatively correlated with CBCL internalizing (r = -.68, p < .01; r = -.65, p < .01, 
respectively) and externalizing behavior problems (r = -.60, p < .01; r = -.66, p < .01, 
respectively; See Table 5).  Also as expected, disengagement coping was positively 
correlated with CBCL internalizing behavior problems (r = -.66, p < .01).  In addition, the 
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correlation between parent-reported disengagement coping and CBCL externalizing 
behavior problems approached significance (r = .34, p = .07).  
Regarding the cross-informant analyses, the correlation between parent-reported 
secondary control coping and YSR externalizing problems approached significance (r = -
.34, p = .07; See Table 6).  Parent-reported primary control and disengagement coping 
were not significantly correlated with either YSR variable.   
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Table 6 
Cross-Informant Correlations for Coping and Emotional and Behavioral Problems 
     1. 2. 3. 4. 5. 6. 7. 8. 9. 10.   
2. S-R Secondary Control Coping        .15              -.07           .24 .32+        -.42* -.42* -.23          -.09 .13    
9. CBCL Internalizing                          -.16         -.46*         .26         -.68**        -.65**       .66**      .40*         .33   .49**   
6. P-R Disengagement Coping            -.14          -.26           .23          -.72**       -.63**        .38* .09  .32           .09            
3. S-R Disengagement Coping             -.42*       -.62               -.27            -.22 .25          -.01 .09          -.04          -.25  
4. P-R Primary Control Coping            .19           .47*         -.43*                -.10        -.66**       -.23 .01 -.35+       -.18  
8. YSR Externalizing                           .04           -.51**       .13          -.17            -.34+       .22           .69**    .07 -.01          
1. S-R Primary Control Coping                          -.19         -.63**        .21           .04          -.26           -.26 -.33 .06           .33           
7. YSR Internalizing                             .01          -.64**        .20          -.19           -.16         .28  .54**  .54**  .08          
5. P-R Secondary Control Coping        .18           .29           -.26          .48**               -.14           -.10         -.08 -.11         -.10         
10. CBCL Externalizing                       -.15         -.46*        .30          -.60**        -.66**       .34+        .11           .32           .64**         
  
Note:  Healthy control correlations are on the top right 
 
 
Healthy Control Group   
 All correlations among the coping and emotional outcome variables were in the 
predicted directions for the healthy control group.  With regard to self-report, the 
correlation between primary control coping and YSR externalizing behavior problems 
approached significance (r = -.33, p = .08; See Table 4).  Additionally, a significant 
negative correlation was found between self-reported secondary control coping and YSR 
internalizing behavior problems (r = -.42, p < .05).  Self-reported disengagement coping 
was not significantly correlated with either YSR variable.   
 Regarding parent-report, the negative correlation between primary control coping 
and CBCL internalizing behavior problems approached significance (r = -.35, p = .06; 
See Table 5).  Parent-reported secondary control coping did not correlate significantly 
with either CBCL variable.  A positive correlation between parent-reported 
disengagement coping and CBCL internalizing behavior problems approached 
significance (r = .32, p = .09).   
 
Between-Group Comparison of Correlations 
Like the preceding two hypotheses, it was predicted that associations among the 
coping and emotional outcome variables would be stronger for the ALL group than for 
the control group.  Between-group comparisons of significant correlations were 
conducted using Fisher’s z-tests. Three sets of correlations were statistically significant or 
approached significance in both groups: self-reported secondary control coping and YSR 
internalizing behavior problems, parent-reported primary control coping and CBCL 
internalizing behavior problems, and parent-reported disengagement coping and CBCL 
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internalizing behavior problems.  No between-groups differences were found regarding 
the strength of these relations (z = -1.14, z = -1.70, and z = 1.69, respectively).   
Hypothesis 7.  The seventh and final hypothesis predicted that coping strategies 
would mediate the relation between executive function and emotional and behavior 
problems. 
 
ALL Group 
Five sets of variables met criteria to be tested for mediation for the ALL group.  
That is, coping could only be tested as a mediator between executive function and 
emotional and behavioral problems for the following five executive function predictors: 
D-KEFS Sorting Test and the four BRIEF subscales, including Working Memory, Shift, 
Inhibit, and Monitor (See Tables 7-12).   
First, parent-reported primary control coping was tested as a mediator of the 
relation between the D-KEFS Sorting Test and CBCL internalizing and externalizing 
problems.  The regression equation in which D-KEFS Sorting Test scores predicted 
CBCL internalizing problems was significantly different from zero, F (1, 26) = 5.49, p < 
.01, accounting for 14.3% of the variance in CBCL internalizing problems. Inclusion of 
parent-reported primary control accounted for an additional 28.8% of the data and 
resulted in a significant decrease in the relation between D-KEFS Sorting and CBCL 
internalizing problems such that D-KEFS Sorting was no longer a significant predictor.  
Therefore, mediation was tested using Sobel’s test, which was significant (z = -2.53, p = 
.01), indicating a fully mediated model.  Likewise, parent-reported primary control 
 56
coping fully mediated the relation between D-KEFS Sorting Test and CBCL 
externalizing problems (z = -2.35, p < .05). 
Second, parent-reported primary control, secondary control, and disengagement 
coping were each tested as mediators of the relation between each of the BRIEF 
subscales and CBCL internalizing and externalizing problems.  The regression equation 
in which BRIEF Working Memory scores predicted CBCL internalizing problems was 
significantly different from zero, F (1, 26) = 22.66, p < .01, accounting for 44.5% of the 
variance in CBCL internalizing problems.  Inclusion of primary control coping accounted 
for an additional 8.2% of the variance, F(2, 25) = 15.11, p < .01, but did not result in a 
decrease in the relation between BRIEF Working Memory and CBCL internalizing 
problems.  As primary control coping significantly predicted CBCL internalizing 
problems in the full equation, significant indirect effects were tested using Sobel’s test.  
The indirect effect of BRIEF Working Memory via primary control coping was 
significantly different from the direct effects (z = 3.69, p < .01), suggesting that primary 
control coping partially mediated the relation between BRIEF Working Memory and 
CBCL internalizing problems. Likewise, parent-reported primary control coping partially 
mediated the relation between BRIEF Working Memory and CBCL externalizing 
problems (z = 3.22, p < .01).  In addition, parent-reported secondary control coping 
partially mediated the relation between BRIEF Working Memory and both CBCL 
internalizing (z = 2.16, p < .05) and externalizing problems (z = 2.19, p < .05).  Parent-
reported disengagement coping also partially mediated the relation between BRIEF 
Working Memory and CBCL internalizing problems (z = 2.55, p =.01) but not 
externalizing problems (z = 1.55, p = ns). 
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 Third, parent-reported primary control, secondary control, and disengagement 
coping were each tested as mediators of the relation between BRIEF Shift and CBCL 
internalizing and externalizing problems.  The regression equation in which BRIEF Shift 
scores predicted CBCL internalizing problems was significantly different from zero, F (1, 
26) = 35.64, p < .01, accounting for 56.2% of the variance in CBCL internalizing 
problems.  Inclusion of primary control coping accounted for an additional 17% of the 
variance, F(2, 25) = 37.21, p < .01, but did not result in a decrease in the relation between 
BRIEF Working Memory and CBCL internalizing problems.  As primary control coping 
significantly predicted CBCL internalizing problems in the full equation, significant 
indirect effects were tested using Sobel’s test.  The indirect effect of BRIEF Shift via 
primary control coping was significantly different from the direct effects (z =2.20, p < 
.05), suggesting that primary control coping partially mediated the relation between 
BRIEF Shift and CBCL internalizing problems.  Similarly, parent-reported primary 
control coping partially mediated the relation between BRIEF Shift and CBCL 
externalizing problems (z = 2.49, p = .01).  Parent-reported secondary control and 
disengagement coping also partially mediated the relations between BRIEF Shift and 
CBCL internalizing problems (z = 2.25, p < .05 and z = 2.19, p < .05, respectively).  
While parent-reported secondary control coping partially mediated the relation between 
BRIEF Shift and CBCL externalizing problems (z = 2.23, p < .05), parent-reported 
disengagement coping did not (z = 1.80, p = ns).     
 Fourth, parent-reported primary control and disengagement coping were tested as 
mediators of the relation between BRIEF Inhibit and CBCL internalizing and 
externalizing problems.  The regression equation in which BRIEF Inhibit scores predicted 
 58
CBCL internalizing problems was significantly different from zero, F (1, 26) = 5.71, p < 
.01, accounting for 15% of the variance in CBCL internalizing problems.  Inclusion of 
primary control coping accounted for an additional 26.5% of the variance, F (2, 25) = 
10.57, p < .01 and resulted in a significant decrease in the relation between BRIEF Inhibit 
and CBCL internalizing problems.  Results from Sobel’s test indicated that this that 
parent-reported primary control coping fully mediated the relation between BRIEF 
Inhibit and CBCL internalizing problems (z = 2.80, p < .01).  Similarly, parent-reported 
primary control coping partially mediated the relation between BRIEF Shift and CBCL 
externalizing problems (z = 2.49, p = .01).  Parent-reported disengagement coping 
partially mediated the relation between BRIEF Inhibit and CBCL internalizing problems 
(z = 2.49, p = .01), but this was not the case for the relation between BRIEF Inhibit and 
CBCL externalizing problems (z = 1.57, p = n.s.). 
 Finally, self-reported secondary control coping and all three of the parent-reported 
coping factors (primary control, secondary control, and disengagement) were tested as 
mediators in the relation between BRIEF Monitor and CBCL internalizing and 
externalizing problems.  The regression equation in which BRIEF Monitor scores 
predicted CBCL internalizing problems was significantly different from zero, F (1, 26) = 
18.96, p < .01, accounting for 38.7% of the variance in CBCL internalizing problems.  
Inclusion of self-reported secondary control coping accounted for an additional 7.8% of 
the variance, F (2, 25) = 13.12, p < .01, but did not result in a decrease in the relation 
between BRIEF Monitor and CBCL internalizing problems.  As self-reported secondary 
control coping significantly predicted CBCL internalizing problems in the full equation, 
significant indirect effects were tested using Sobel’s test.  The indirect effect of BRIEF 
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Monitor via self-reported secondary control coping was significantly different from the 
direct effects (z = 2.89, p < .01), suggesting that secondary control coping partially 
mediated the relation between BRIEF Monitor and CBCL internalizing problems.  
Parent-reported primary control, secondary control, and disengagement coping all 
partially mediated the relation between BRIEF Monitor and CBCL internalizing 
problems (z = 3.01, p < .01; z = 2.90, p < .01; z = 2.78, p < .01, respectively).  Parent-
reported secondary control coping partially mediated the relation between BRIEF 
Monitor and CBCL externalizing problems (z = 2.50, p < .05), but parent-reported 
primary control and disengagement coping did not (z = 1.80 and z = 1.67, respectively, 
both ns).   
 
Healthy Control Group 
Only one set of variables met criteria needed to test for mediation for the healthy 
control group.  Specifically, parent-reported primary control coping was tested as a 
mediator of the relation between BRIEF Shift scores and CBCL internalizing problems.  
The regression equation in which BRIEF Shift scores predicted CBCL internalizing 
problems was significantly different from zero, F (1, 25) = 9.13, p < .01, accounting for 
26.7% of the variance in CBCL internalizing problems. Inclusion of parent-reported 
primary control coping did not account for a significant increase in the percentage of 
variance accounted for (Δ R2 = .03, n.s.) and did not result in a decrease in the relation 
between BRIEF Shift and CBCL Internalizing problems.  Therefore, these results support 
an independent effect of CBCL internalizing problems by BRIEF Shift scores and do not 
provide evidence of mediation.   
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Table 7 
Regression Equations Testing Primary Control Coping as a Mediator Between Executive 
Function and CBCL Internalizing Problems  
 
Equation 1 – CBCL Internalizing  Final R2 = .42  F (2) = 10.76, p < .01 
Step 1: R2 change = .17*  β  sr 
 D-KEFS Sorting Test  -.42*  -.41 
Step 2: R2 change = .29** 
 D-KEFS Sorting Test  -.09 -.08 
 P-R Primary Control Coping -.63** -.54 
Equation 2 – CBCL Internalizing Final R2 = .51 F (2) = 15.11, p < .01 
Step 1: R2 change = .47**  β  sr 
 BRIEF Working Memory -.68**  -.68 
Step 2: R2 change = .08* 
 BRIEF Working Memory  -.41* -.30 
 P-R Primary Control Coping -.39* -.29 
Equation 3 – CBCL Internalizing Final R2 = .65  F (2) = 26.18, p < .01 
Step 1: R2 change = .58**  β sr 
 BRIEF Shift  -.76** -.76 
Step 2: R2 change = .10* 
 BRIEF Shift  -.56** -.47 
 P-R Primary Control Coping -.37* -.31 
Equation 4 – CBCL Internalizing Final R2 = .46  F (2) = 10.57, p <.01 
Step 1: R2 change = .18*  β sr 
 BRIEF Inhibit  -.42* -.42 
Step 2: R2 change = .28** 
 BRIEF Inhibit  -.04  -.03 
 P-R Primary Control Coping -.71** -.53 
Equation 5 – CBCL Internalizing Final R2 = .65  F (2) = 26.23, p <.01 
Step 1: R2 change = .61**  β sr 
 BRIEF Monitor  -.78** -.78 
Step 2: R2 change = .06* 
 BRIEF Monitor   -.59**  -.47 
 P-R Primary Control Coping -.32* -.25 
Note: P-R = Parent-reported; S-R = Self-reported; β  = standardized beta; sr = semi-partial correlation 
* <.05,  ** < .01   
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Table 8 
Regression Equations Testing Primary Control Coping as a Mediator Between Executive 
Function and CBCL Externalizing Problems  
 
Equation 1 – CBCL Externalizing  Final R2 = .18  F (2) = 7.79, p < .01 
Step 1: R2 change = .20*  β  sr 
 D-KEFS Sorting Test  -.45*  -.45 
Step 2: R2 change = .18* 
 D-KEFS Sorting Test  -.19 -.20 
 P-R Primary Control Coping -.50** -.48 
Equation 2 – CBCL Externalizing Final R2 = .48  F (2) = 14.00, p <.01 
Step 1: R2 change = .63**  β sr 
 BRIEF Working Memory -.65** -.63 
Step 2: R2 change = .10* 
 BRIEF Working Memory -.42*  -.33 
 P-R Primary Control Coping -.40* -.31 
Equation 3 – CBCL Externalizing Final R2 = .52  F (2) = 13.31, p <.01 
Step 1: R2 change = .41**  β sr 
 BRIEF Shift  -.66** -.66 
Step 2: R2 change = .48* 
 BRIEF Shift  -.47**  -.40 
 P-R Primary Control Coping -.34* -.29 
Equation 4 – CBCL Externalizing Final R2 = .45  F (2) = 10.16, p <.01 
Step 1: R2 change = .39**  β sr 
 BRIEF Inhibit  -.62** -.62 
Step 2: R2 change = .06 
 BRIEF Inhibit  -.40*  -.30 
 P-R Primary Control Coping -.33 -.25 
Equation 5 – CBCL Externalizing Final R2 = .58  F (2) = 19.49, p <.01 
Step 1: R2 change = .58**  β sr 
 BRIEF Monitor  -.76** -.76 
Step 2: R2 change = .03 
 BRIEF Monitor   -.63**  -.50 
 P-R Primary Control Coping -.21 -.17 
Note: P-R = Parent-reported; S-R = Self-reported; β  = standardized beta; sr = semi-partial correlation 
* <.05,  ** < .01   
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Table 9 
Regression Equations Testing Secondary Control Coping as a Mediator Between Executive 
Function and CBCL Internalizing Problems  
 
Equation 1 – CBCL Internalizing  Final R2 = .54  F (2) = 16.87, p < .01 
Step 1: R2 change = .47**  β  sr 
 BRIEF Working Memory -.68**  -.68 
Step 2: R2 change = .11* 
 BRIEF Working Memory -.47** -.40 
 P-R Secondary Control Coping -.39* -.33 
Equation 2 – CBCL Internalizing Final R2 = .67  F (2) = 28.56, p <.01 
Step 1: R2 change = .58*  β sr 
 BRIEF Shift  -.76** -.76 
Step 2: R2 change = .12** 
 BRIEF Shift  -.59**  -.53 
 P-R Secondary Control Coping -.38** -.34 
Equation 3 – CBCL Internalizing Final R2 = .47  F (2) = 13.12, p <.01 
Step 1: R2 change = .39**  β sr 
 BRIEF Monitor  -.64** -.64 
Step 2: R2 change = .08* 
 BRIEF Monitor  -.48**  -.42 
 S-R Secondary Control Coping -.33* -.29 
Equation 4 – CBCL Internalizing Final R2 = .68  F (2) = 29.89, p <.01 
Step 1: R2 change = .61**  β sr 
 BRIEF Monitor  -.78** -.78 
Step 2: R2 change = .09** 
 BRIEF Monitor  -.62**  -.54 
 P-R Secondary Control Coping -.35** -.30 
Note: P-R = Parent-reported; S-R = Self-reported; β  = standardized beta; sr = semi-partial correlation 
* <.05,  ** < .01   
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Table 10 
Regression Equations Testing Secondary Control Coping as a Mediator Between Executive 
Function and CBCL Externalizing Problems  
 
Equation 1 – CBCL Externalizing  Final R2 = .69  F (2) = 30.47, p < .01 
Step 1: R2 change = .63**  β  sr 
 BRIEF Working Memory -.80**  -.80 
Step 2: R2 change = .08* 
 BRIEF Working Memory -.62** -.52 
 P-R Secondary Control Coping -.33* -.28 
Equation 2 – CBCL Externalizing Final R2 = .57  F (2) = 18.94, p <.01 
Step 1: R2 change = .43**  β sr 
 BRIEF Shift  -.66** -.66 
Step 2: R2 change = .17** 
 BRIEF Shift  -.45**  -.40 
 P-R Secondary Control Coping -.46** -.41 
Equation 3 – CBCL Externalizing Final R2 = .67  F (2) = 27.91, p <.01 
Step 1: R2 change = .58**  β sr 
 BRIEF Monitor  -.76** -.76 
Step 2: R2 change = .11** 
 BRIEF Monitor   -.58**  -.50 
 P-R Secondary Control Coping -.38** -.33 
Note: P-R = Parent-reported; S-R = Self-reported; β  = standardized beta; sr = semi-partial correlation 
* <.05,  ** < .01   
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Table 11 
Regression Equations Testing Disengagement Coping as a Mediator Between Executive Function 
and CBCL Internalizing Problems  
 
Equation 1 – CBCL Internalizing  Final R2 = .57  F (2) = 18.51, p < .01 
Step 1: R2 change = .47**  β  sr 
 BRIEF Working Memory -.68**  -.68 
Step 2: R2 change = .13** 
 BRIEF Working Memory -.47** -.41 
 P-R Disengagement Coping .42** .36 
Equation 2 – CBCL Internalizing Final R2 = .73  F (2) = 37.21, p <.01 
Step 1: R2 change = .58**  β sr 
 BRIEF Shift  -.76** -.76 
Step 2: R2 change = .17** 
 BRIEF Shift  -.60**  -.56 
 P-R Disengagement Coping           .44** .41 
Equation 3 – CBCL Internalizing Final R2 = .40  F (2) = 9.82, p <.01 
Step 1: R2 change = .18*  β sr 
 BRIEF Inhibit  -.42* -.42 
Step 2: R2 change = .26** 
 BRIEF Inhibit  -.11  -.10 
 P-R Disengagement Coping .60** .51 
Equation 4 – CBCL Internalizing Final R2 = .70  F (2) = 32.35, p <.01 
Step 1: R2 change = .61**  β sr 
 BRIEF Monitor  -.78** -.78 
Step 2: R2 change = .11** 
 BRIEF Monitor  -.61**  -.54 
 P-R Disengagement Coping .37** .33 
Note: P-R = Parent-reported; S-R = Self-reported; β  = standardized beta; sr = semi-partial correlation 
* <.05,  ** < .01   
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Table 12 
Regression Equations Testing Disengagement Coping as a Mediator Between Executive Function 
and CBCL Externalizing Problems  
 
Equation 1 – CBCL Externalizing  Final R2 = .61  F (2) = 22.05, p < .01 
Step 1: R2 change = .63**  β  sr 
 BRIEF Working Memory -.80**  -.80 
Step 2: R2 change = .01 
 BRIEF Working Memory -.84** -.73 
 P-R Disengagement Coping .09 .07 
Equation 2 – CBCL Externalizing Final R2 = .40  F (2) = 10.00, p <.01 
Step 1: R2 change = .43**  β sr 
 BRIEF Shift  -.66** -.66 
Step 2: R2 change = .01 
 BRIEF Shift  -.62**  -.58 
 P-R Disengagement Coping .12 .11 
Equation 3 – CBCL Externalizing Final R2 = .34  F (2) = 7.89, p <.01 
Step 1: R2 change = .39**  β sr 
 BRIEF Inhibit  -.62** -.76 
Step 2: R2 change = .00 
 BRIEF Inhibit  -.61**  -.52 
 P-R Disengagement Coping .02 .02 
Equation 4 – CBCL Externalizing Final R2 = .55  F (2) = 17.33, p <.01 
Step 1: R2 change = .58**  β sr 
 BRIEF Monitor  -.76** -.76 
Step 2: R2 change = .00 
 BRIEF Monitor  -.78**  -.68 
 P-R Disengagement Coping .03 .02 
Note: P-R = Parent-reported; S-R = Self-reported; β  = standardized beta; sr = semi-partial correlation 
* <.05,  ** < .01   
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CHAPTER IV 
 
DISCUSSION 
 
 This study examined the role of executive function in coping with stress and 
emotional and behavioral problems in a sample of childhood ALL survivors and a 
matched sample of healthy controls.  It was predicted that ALL survivors would exhibit 
poorer executive function, less adaptive patterns of coping, and greater emotional and 
behavioral problems than children with no history of leukemia.  In addition, it was 
expected that coping would mediate the relation between executive function and 
emotional problems.  That is, poorer executive function would lead to greater use of 
disengagement strategies, such as denial and avoidance, and less reliance on primary 
control (e.g., problem solving) and secondary control (e.g., acceptance; cognitive 
restructuring) coping, which would then lead to more internalizing and externalizing 
behavior problems.  This pattern was expected to be true particularly for the ALL group, 
who are at risk for executive function impairment from their neurotoxic treatment.     
With regard to the between-group differences among the executive function, 
coping, and emotional variables, the data partially support the hypothesis that childhood 
ALL survivors demonstrate more maladaptive functioning than the healthy control group.  
Specifically, consistent with the recent meta-analysis published by Campbell and 
colleagues (in press), ALL survivors had significantly lower scores in several domains of 
executive function, including working memory, measured behaviorally and by parent-
report, as well as a behavioral measure of cognitive flexibility.  ALL survivors also 
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performed more poorly on a test of overall intellectual functioning and a measure of 
information processing speed.  Although not all between-group comparisons of executive 
function reached statistical significance, effect sizes comparing the ALL and healthy 
control groups were all in the negative direction, indicating poorer executive function 
across the various domains and methods of measurement.  These effect sizes ranged from 
negligible to medium, with small effects found for both measures of cognitive flexibility 
and parent-reported executive inhibition and medium effects found for both measures of 
working memory.  Thus, the results of the present study provide a strong replication of 
the findings reported by Campbell et al. in their meta-analysis. Other domains of 
cognitive function, not assessed in the current study, also showed deficits for ALL 
survivors, indicating that the adverse effects of treatment extend beyond  the variables 
measured here. 
There were no statistically significant differences between the groups with regard 
to the proportion of each type of coping strategy endorsed by children and parents. 
However, small albeit non-significant, negative effects were found for both self-reported 
and parent-reported secondary control coping, suggesting ALL participants and their 
parents tended to endorse comparatively more strategies like acceptance and cognitive 
restructuring in response to stress than did healthy control participants.  Caution must be 
used interpreting these results, however, since the small sample size did not yield enough 
power to establish if these small effects are reliable.  In general, the present study does 
not suggest that ALL survivors differ from healthy controls in their patterns of coping 
with stress. 
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The ALL and healthy control groups did not significantly differ on self- or parent-
reported internalizing or externalizing symptoms.  In fact, a small, positive but non-
significant effect for CBCL internalizing symptoms was found, suggesting that ALL 
survivors experience less emotional distress, such as symptoms of depression and 
anxiety, than do children with no history of leukemia.  This finding is consistent with 
previous research that suggests that childhood cancer survivors are emotionally doing as 
well, if not better than healthy children (e.g., Phipps, Steele, Hall, & Leigh, 2001; 
Recklitis et al., 2006).  Whether such findings truly indicate that ALL survivors 
experience little or no symptoms of psychopathology is still being debated in the field of 
pediatric psycho-oncology. Phipps and colleagues at St. Jude posit that cancer survivors, 
along with other pediatric patients diagnosed with chronic illnesses, such as Type I 
diabetes, cystic fibrosis, and juvenile rheumatoid arthritis, have a repressive adaptational 
style, which is characterized by a denial of personal problems or flaws, including 
psychological distress, and an endorsement of socially desirable behavior, which may be 
interpreted as defensiveness (e.g., Phipps & Steele, 2002; Phipps, Steele, Hall, & Leigh, 
2001).  Testing this theory is beyond the scope of the current study; however, it is 
important to consider the current findings in light of this theory.  One study by Phipps 
and colleagues (2001) found that childhood cancer patients exhibit a repressive 
adaptational style within 2 to 4 weeks of diagnosis, which the authors concluded is a 
reaction to the diagnosis rather than a premorbid personality trait.  If the current study 
findings reflect the phenomenon of repressive adaptation, this would suggest that children 
treated for ALL continue exhibiting this style well after their treatment ends.       
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However, when the CBCL and YSR internalizing and externalizing problem 
scales were further delineated into the various syndrome scales in the current study’s 
analyses, the picture is less clear.  Small, negative effects were found for some of the 
CBCL and YSR scales, suggesting more problems for the ALL survivors, and small, 
positive ones were found for others.  However, these findings differed depending on 
whether the parent or child reported the problems.  Specifically, according to parent 
report on the CBCL, ALL survivors appear to have more difficulties than healthy controls 
with regard to social problems, attention problems, and rule-breaking behaviors, but that 
they actually exhibit fewer somatic symptoms than healthy controls.  In contrast, 
according to the reports of the children and adolescents on the YSR, ALL survivors 
endorsed more difficulties with symptoms of anxiety and somatic problems, whereas they 
endorse fewer depressive symptoms, social problems, and aggressive behavior than do 
healthy controls.  In short, the question about whether childhood cancer survivors 
experience emotional and behavioral problems seems to depend on the informant and 
what specific problems are assessed.  However, because of limited statistical power, 
comparison of the ALL and healthy control groups on these more specific indicators of 
types of emotional and behavioral problems did not reach statistical significance.  Future 
research with larger samples is needed to examine some of the trends observed in the 
present data to determine if there are differences between ALL survivors and healthy 
controls in specific domains of psychological problems.          
Although the current study did not find significant between-group differences on 
all variables examined in this study, it is noteworthy that there were many more 
statistically significant correlations among the executive function, coping, and 
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emotional/behavioral variables for the ALL group compared to the healthy control group.  
While many of these correlations were among the parent-reported independent and 
dependent measures (BRIEF executive function, parent-reported coping on the RSQ, and 
CBCL internalizing and externalizing behaviors), indicating that shared-method variance 
played a role in these associations, there was also evidence of important associations 
across informants and method of measurement.  These are briefly summarized here, as 
they are considered more robust findings.   
Self-reported secondary control coping was significantly and positively correlated 
with all four parent-reported domains of executive function: working memory, cognitive 
flexibility, behavioral inhibition, and self-monitoring.  In addition, self-reported 
disengagement coping was significantly and negatively correlated with both behavioral 
and parent-report measures of working memory and self-monitoring, and parent-reported 
behavioral inhibition.  Parent-reported primary control coping was significantly and 
positively correlated with the behavioral measures of working memory and cognitive 
flexibility, and parent-reported disengagement coping was significantly and negatively 
correlated with the behavioral measure of working memory.  These findings support the 
theory that coping is governed by executive function processes and is therefore regulated 
by the dorsolateral prefrontal cortex and its cortical and subcortical connections thought 
to be responsible for higher-order cognitive functioning (Compas, 2006; Copeland & 
Compas, 2007).   
With regard to the correlations among the executive function and emotional/ 
behavioral variables, significant findings were also found across informants and methods.  
Specifically, self-reported internalizing behavior problems were significantly associated 
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with parent-reported self-monitoring, and self-reported externalizing behavior problems 
were significantly associated with behavioral measures of behavioral inhibition and 
working memory.  Both parent-reported internalizing and externalizing problems were 
significantly associated with the behavioral measure of cognitive flexibility.  Finally, 
regarding the correlations among coping and emotional/behavioral variables, self- and 
parent-reported secondary control coping were associated with self- and parent-reported 
externalizing behavior problems.  Self-reported secondary control coping was also 
significantly associated with parent-reported internalizing problems.  These correlations 
suggest that impairment in executive functioning, coping, and emotion regulation 
resulting from neurotoxic ALL treatment is related to increases in emotional and 
behavioral problems in childhood ALL survivors.          
Most importantly, the data provide some support for the hypothesis that coping 
mediates the relation between executive function and emotional outcome in survivors of 
childhood ALL.  As expected, the majority of the mediation analyses were tested among 
the parent-reported executive function, coping, and emotional/behavioral variables, again 
suggesting shared method variance.  However, there were also two instances of mediation 
across methods or informants.  The findings regarding the mediation analyses are 
summarized below. 
First, primary control coping, as reported by the parents of ALL survivors, fully 
mediated the relations between the behavioral measure of cognitive flexibility and parent-
reported internalizing and externalizing behavior.  Primary control coping also fully 
mediated the relation between parent-reported behavioral inhibition and parent-reported 
internalizing behavior.  Consistent with the findings reported by Copeland and Compas 
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(2007), these findings suggest that difficulties switching back and forth between tasks 
and the inability to inhibit one’s prepotent responses leads to the use of less problem-
solving, emotional modulation, and emotional expression in coping with stress, which in 
turn leads to emotional distress and perhaps even behavior problems.   
All other findings indicated partial mediation, meaning that although coping 
appears to play an important role in the relation between executive function and 
emotional/behavioral outcomes, there is also a direct relation between these variables 
independent of coping.  Both self- and parent-reported secondary control coping partially 
mediated the relation between parent-reported self-monitoring and parent-reported 
internalizing behavior.  Similarly, parent-reported secondary control coping partially 
mediated the relations between the following parent-reported executive functions: 
working memory; cognitive flexibility; behavioral inhibition and 
internalizing/externalizing behavior problems.  These findings suggests that poorer 
executive function in several domains leads to decreased use of cognitive restructuring 
and acceptance and/or increased reliance on maladaptive patterns of coping, such as 
denial and avoidance, which then leads to emotional distress.  The fact that a direct 
relation remains between executive function internalizing/externalizing behaviors may 
also mean that difficulties in working memory, self-monitoring, cognitive flexibility, and 
behavioral inhibition lead to other factors that are not accounted for in this study, such as 
an increase of cognitive distortions or difficulties in attention, that then leads to emotional 
and behavioral problems.  Another interpretation of the direct relation is that a 
neurophysiological process occurring in the prefrontal cortex or white matter leads to 
impaired executive functioning and emotional dysregulation.   
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 It is possible that one reason the ALL group evinced more important relations 
among the executive function, coping, and emotional/behavioral variables despite the 
lack of statistically significant between-group findings is that only a subgroup of 
childhood ALL survivors experience executive function deficits as a result of their 
treatment, which is associated with less adaptive patterns of coping with stress and 
emotional difficulties.  Research with adult cancer survivors is instructive with regard to 
possible individual differences in vulnerability to the adverse effects of chemotherapy.  
Research examining the neurocognitive sequelae of adult cancer treatment, a 
phenomenon referred to  as “chemobrain,” suggests that adults who carry a genetic 
marker for Alzheimer’s disease (ε4 allele of the APOE gene), may be at increased 
vulnerability to chemotherapy-induced neurocognitive impairment compared to adult 
cancer survivors who were not carriers of the gene (Ahles et al. 2003).  Further, Ahles 
and Saykin (2007) also discuss other potential mechanisms by which individuals treated 
with chemotherapy experience cognitive changes, such as DNA damage and deficits in 
DNA repair, as well as deregulation of the immune response caused by neurotoxic 
treatments.  Although this work has been done in survivors of adult cancers, such as 
breast and lung neoplasms, it is possible that a subset of children treated for cancers, 
including leukemia, with chemotherapy agents may possess similar vulnerabilities to 
cognitive impairment.  
  
Strengths of the Current Study 
Methodologically, the current study went beyond previous studies examining the 
neurocognitive sequelae of childhood cancer in several ways.  First, the sample of 
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childhood cancer survivors was homogeneous with regard to diagnosis, type of treatment 
received, and stage of treatment.  That is, only children and adolescents who were 
successfully treated for a first diagnosis of ALL with chemotherapy only and were off 
treatment by the time of study participation were included.  Many studies in the literature 
have combined patients with different types of leukemias and have frequently included 
lymphomas in the study sample despite the fact that these diagnoses are very different in 
terms of their prognoses, type of treatment, and length of treatment.  Likewise, it is not 
uncommon for children with CNS tumors to be included in the same study sample as 
leukemia patients.  Further, all of the ALL participants in the current study completed 
treatment prior to recruitment, whereas some studies include patients who are still 
receiving ALL treatment with those who are off treatment, making it difficult to 
distinguish acute, temporary cognitive disturbance related to certain types of 
chemotherapy to long-term neurocognitive sequelae. 
 Another methodological strength of the current study was the selection of a 
healthy control sample matched to the ALL participants on sex, age, and when possible, 
socioeconomic status in an effort to reduce the number of confounding variables.  
Although the groups matched very well with regard to household income, the primary 
caregivers in the healthy control group had significantly higher educational attainment 
than did the parents in the healthy control sample.  However, even when educational 
status was controlled for in the analyses, there were still significant differences between 
the groups on Full Scale IQ and both measures of working memory, indicating that the 
between-group differences in neurocognitive functioning were not solely attributable to 
the difference in parent education.       
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Additionally, the study employed multiple methods (behavioral assessment and 
parent report of executive function), as well as multiple informants (child and parent 
report of coping and emotional/behavioral symptoms).  Both of these methodological 
strengths are essential in better understanding the factors contributing to the 
neurocognitive and emotional sequelae of childhood ALL.        
Another important strength of this study was that it employed measures of 
specific domains of executive function with a normative sample of participants.  Previous 
studies examining ALL treatment effects on executive function used a variety of 
measures assessing various domains of executive function, making it difficult to compare 
studies or generalize findings given that few studies defined “executive function” in the 
same way.  In addition, a variety of norms to interpret the data yielded from these studies 
were used, many of which were comprised of very small sample sizes.  The D-KEFS, 
was normed on a sample of 1,750 individuals stratified by age and produces standard 
scores for each of its subtests, making the results comparable and easily interpretable.      
 
Limitations of the Current Study 
The current study also had several limitations that must be addressed.  First, as 
noted throughout  this paper, the sample size of 30 participants in each group limited 
power to detect smaller but potentially meaningful effects, both in regard to between-
group findings and correlations among the variables within each group.  Effect sizes were 
reported in order to demonstrate potentially meaningful findings, which will need to be 
corroborated by adding more participants and thus increasing power.  It should be noted, 
however, that this study’s sample of childhood ALL survivors is on par with or larger 
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than 50 to 60% of the published papers included in the meta-analysis reviewing the 
neurocognitive effects of childhood ALL treatment (Campbell et al., in press).  Given the 
relatively low base rate of childhood cancer and most other pediatric disorders, 
collaborative studies among multiple institutions are essential in recruiting large samples 
of children treated for a specific illness.  The research team working on the current study 
plans to continue recruiting participants and is considering partnering with research teams 
at other academic children’s hospitals. 
As mentioned above, although the healthy control sample was matched 
exceptionally well with regard to sex, age, and family income, the healthy control parents 
had a greater level of educational attainment.  Approximately 75% of the healthy control 
participants and their parents were recruited through the Vanderbilt Medical Center, and 
as a result, the majority of those who volunteered for this study worked in professional 
positions.  The other method of recruitment asking ALL participants to nominate same-
age, same-sex friends and classmates, only yielded 25% of the healthy control sample, as 
many of the ALL survivors declined this method.   
  
Clinical Implications 
The results from this study suggest that the neurocognitive sequelae of childhood 
ALL extend beyond academic and vocational outcomes.  The preliminary results of this 
study partially support the assertion that impaired executive function in at least a subset 
of childhood ALL survivors may limit their ability to effectively cope with stress.  These 
findings demonstrate the necessity of intervention techniques that teach childhood cancer 
survivors cognitive-behavioral and metacognitive techniques (Butler & Copeland, 2002), 
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as well as other coping skills, not solely for the goal of cognitive remediation and 
improves school performance, but also to prevent emotional problems that could result 
from maladaptive patterns of coping. 
Additionally, there is some evidence in the literature to suggest that childhood 
ALL survivors, particularly during adolescence, are susceptible to social problems with 
peers (e.g., Shelby et al., 1998).  The current study assessed coping strategies specifically 
with regard to social stressors, as it is a common source of stress for all adolescents, 
healthy or ill.  Some of the findings suggested that the ALL survivors in this study used 
fewer adaptive coping strategies, such as problem-solving and cognitive restructuring and 
relied more on avoidance and denial in response to normative social stressors, such as 
arguing with a friend or feeling left out.  Barakat and colleagues (2003) created a 
manualized group intervention for survivors of pediatric brain tumors and their parents, 
and preliminary findings demonstrated small to moderate improvements in social skills 
(e.g., nonverbal communication; engaging in conversation) and social functioning.  Such 
an intervention might be equally beneficial for the subset of ALL survivors that evince 
peer-related problems.   
 
Directions for Future Research 
This study paves the way for continued research on the relation between 
neurocognitive impairment and coping in children treated for ALL.  The research team 
for the current study is continuing to recruit participants to increase the sample size and 
improve power, which will enable us to better interpret the data.  However, the 
preliminary data presented in this paper already highlight the importance of examining 
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childhood cancer survivors’ ability to cope with life stress, especially given their risk for 
neurocognitive problems that can impair their ability to cope and regulate their emotions.   
 In addition, another study that is currently underway in our laboratory is using 
structural and functional imaging, as well as DTI, to further examine the 
neurophysiological underpinnings of executive function impairment, coping, and emotion 
regulation.  Those ALL survivors from the current study who demonstrate significant 
deficits in executive function during the neurocognitive assessment, as well as their 
matched healthy controls, are being recruited to participate in the imaging study and will 
be administered a series of executive function tasks while functionally measuring 
activation in the prefrontal cortex.  This is an important addition to the study, as it is 
expected to demonstrate specific neurophysiological effects of treatment in ALL 
survivors that will be associated with poorer performance on the neurocognitive tests 
administered for the current study.        
 Finally, research by Ahles and colleagues (2003, 2007) examining genetic 
markers for “chemobrain” in adults should be extended to survivors of childhood ALL 
and other pediatric cancers, as it appears that only a subgroup of children receiving 
neurotoxic therapeutic agents end up with neurocognitive impairment.   
 
Conclusion 
 The first portion of this study was a replication and extension of previous research 
comparing ALL survivors to healthy controls with regard to executive function.  
Consistent with a recently published meta-analytic review (Campbell et al. in press), ALL 
survivors performed more poorly than healthy controls on several domains of executive 
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function, even when differences in parent education were taken into account.  The results 
of this study also provide preliminary evidence that some survivors of childhood ALL are 
susceptible to impaired executive function and therefore experience difficulties in coping 
effectively with stressful life events, leading to emotional distress and behavior problems.  
This study asserts that the ability to employ adaptive coping skills is dependent on intact 
executive functioning, including the domains of working memory, cognitive flexibility, 
self-monitoring, and behavioral inhibition.  When the ability to perform these higher-
level cognitive tasks is damaged, children and adolescents appear to rely more heavily on 
maladaptive patterns of coping, such as denial and avoidance, and less on strategies 
considered more adaptive, such as problem-solving, acceptance, and cognitive 
restructuring.      
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APPENDICES 
 
Appendix A 
 
 
Demographic Intake Form 
 
 
Thank you for agreeing to help us with this study.  We appreciate you taking time to come 
into the clinic today.  We would like to ask you some questions about your child’s life.  Some 
questions ask about your family, your child’s health, and progress in school.  You should 
know that everything you say will be kept private and will only be seen by people working 
on our study.  If you aren’t sure about the answer to a question, you might have to take 
your best guess.  That’s OK.  Also, if you don’t feel comfortable answering a question it’s 
OK to skip it.  Do you have any questions before we get started? 
 
Today’s Date:   __/__/____ (mm/dd/yyyy) 
 
Examiner:   _____________________ 
 
Historian (circle one):  Mother           Father          Stepmother          Stepfather 
    Other (please list relationship):___________________ 
 
Child’s Sex (circle one): Female           Male 
 
Child’s Age:   __________ 
 
Child’s Date of Birth:  __/__/____ (mm/dd/yyyy) 
 
Demographic and Family Information
 
First I am going to ask you some questions about [child’s name] home and family life… 
 
1.  Who is the child’s main  Mother           Father          Stepmother          Stepfather 
     caregiver?     Other (please list relationship):___________________ 
 
2.  What is the date of birth of the main caregiver?  __/__/____ (mm/dd/yyyy) 
 
3.  What is the date of birth of the child’s biological mother (if not the main caregiver)?   
     __/__/____ (mm/dd/yyyy) 
 
4.  Which of the following best described the child’s race or ethnicity? 
     ____White or Caucasian 
     ____Black or African-American 
     ____Latino or Hispanic 
     ____Asian, Asian American, or Pacific Islander 
     ____Native American or Alaska Native 
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     ____Or something else, please describe:  __________________________________________ 
 
5.  Which of the following best described the main caregiver’s race or ethnicity? 
     ____White or Caucasian 
     ____Black or African-American 
     ____Latino or Hispanic 
     ____Asian, Asian American, or Pacific Islander 
     ____Native American or Alaska Native 
     ____Or something else, please describe:  __________________________________________ 
6.  Which of the following best described the biological mother’s race or ethnicity (if not the main  
     caregiver)? 
     ____White or Caucasian 
     ____Black or African-American 
     ____Latino or Hispanic 
     ____Asian, Asian American, or Pacific Islander 
     ____Native American or Alaska Native 
     ____Or something else, please describe:  __________________________________________ 
 
7.  How many siblings does [child’s name] have?  _____ 
 
     If he/she has siblings, please list their first name, gender, and age below: 
 
     Name  Gender   Age
     __________________________________________ 
     __________________________________________ 
     __________________________________________ 
     __________________________________________ 
     __________________________________________ 
     __________________________________________ 
 
8.  How many people, including both children and adults currently live in the same house as     
     [child’s name]?  _____ 
 
9.  Which best describes the marital status of the child’s main caregiver? 
     ____Married/partnered 
     ____Separated 
     ____Divorced 
     ____Widowed 
     ____Single/Never Married 
 
10. Which best describes the marital status of the child’s biological mother (if not the main  
     caregiver)? 
     ____Married/partnered 
     ____Separated 
     ____Divorced 
     ____Widowed 
     ____Single/Never Married 
 
11. What is the highest grade or level of school of the main caregiver? 
     ____Grade School (grades 1-8) 
     ____High School, but didn’t graduate  
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     ____High School, graduated or obtained GED 
     ____Training after high school, other than college 
     ____Some College 
     ____College Graduate 
     ____Post Graduate Level 
 
 
12. What is the highest grade or level of school of the biological mother (if not the main  
     caregiver)? 
     ____Grade School (grades 1-8) 
     ____High School, but didn’t graduate  
     ____High School, graduated or obtained GED 
     ____Training after high school, other than college 
     ____Some College 
     ____College Graduate 
     ____Post Graduate Level 
 
13. For this question, please check the box next to the letter that best described your  
     family’s income. 
 
 1 Less than $10,000 
 2 $10,000 to $20,000 
 3 $20,000 to $30,000 
 4 $30,000 to $40,000 
 5 $40,000 to $50,000 
 6 $50,000 to $60,000 
 7 $60,000 to $70,000 
 8 $70,000 to $80,000 
 9 More than $80,000 
 10 I don’t know 
 11 I’d rather not say 
 
      
 
 
 
 
 
 
 
 
 
 
14.  What is the job of the person contributing most to the family income?  __________________ 
 
Developmental and Medical History
 
Now I’d like to ask you some questions about [child’s name] medical history since he/she 
was born... 
 
1.  How long did the pregnancy with [child’s name] last? (Full term = 40 weeks)  _______ weeks 
 
2.  How much did your child weigh at birth?  ____ lbs    ____ oz 
 
3.  Has your child had any other serious medical problems that        ____Yes     _____No 
     required hospitalization (IF ALL PARTICIPANT, say in addition to ALL)? 
 
    If yes, please describe: _________________________________________________________ 
                                         __________________________________________________________ 
                                         __________________________________________________________ 
 
4.  Has your child ever experienced a head injury that led to loss of       ____Yes     _____No 
 83
     consciousness and/or hospitalization?   
 
    If yes, please describe: _________________________________________________________ 
                                         __________________________________________________________ 
                                         __________________________________________________________ 
 
 
5.  Has [child’s name] ever taken any medications for ADD or ADHD      ____Yes     _____No 
     (e.g., Ritalin, Adderall, Concerta)  
      
     If yes, please list each medication, the reason it was prescribed, approximate start and end  
     dates, whether the child is currently taking the medication, and if it was taken today record the    
     approximate time it was taken. 
 
     Medication  Reason Prescribed Start Date End Date Current (Time?)
     ____________________________________________________________________________ 
     ____________________________________________________________________________ 
     ____________________________________________________________________________ 
 
6.  Has your child ever been diagnosed and/or treated for any psychological problems, such as  
     depression or anxiety? 
 
     If yes, please describe the diagnosis and type of treatment:  ____________________________ 
     ____________________________________________________________________________ 
     ____________________________________________________________________________ 
 
     If medication was required, please list each medication, the reason it was prescribed,  
     approximate start and end dates, whether the child is currently taking the medication, and if it  
     was taken today record the approximate time it was taken. 
 
     Medication  Reason Prescribed Start Date End Date Current (Time?)
     ____________________________________________________________________________ 
     ____________________________________________________________________________ 
     ____________________________________________________________________________ 
 
Educational Information
 
Lastly, I would like to ask you some questions about [child’s name] education… 
 
1.  Is [child’s name] currently attending school?                     ____Yes     _____No 
        
     If yes, what grade is he/she currently in?  _____ 
 
2.  Has your child ever repeated a grade?        ____Yes     _____No 
 
     If yes, what grade(s) and why?___________________________________________________ 
 
     If graduated or dropped out, indicate highest grade completed:  _____ 
 
     If dropped out, obtained GED?          ____Yes     _____No 
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3.  ALL PARTICIPANTS ONLY: During ALL treatment, did your       ____Yes     _____No 
      child receive any special education services? 
 
     If yes, please explain the services used: __________________________________________ 
                                                                       ___________________________________________ 
                                                                       ___________________________________________ 
 
4.  ALL PARTICIPANTS ONLY: Since ALL treatment, has your          ____Yes     _____No 
     child receive any special education services? 
 
     If yes, please explain the services used:  ___________________________________________ 
                                                                      ___________________________________________ 
                                                                      ___________________________________________ 
 
5.  ALL PARTICIPANTS ONLY: Did your child receive brain               ____Yes     _____No 
     scans (e.g., MRI, CT) before, during, or after ALL treatment? 
 
     If yes, please explain: __________________________________________________________ 
     ____________________________________________________________________________ 
     ____________________________________________________________________________ 
 
6.  Has your child ever had an educational or neuropsychological      ____Yes     _____No 
     evaluation like what we’ll be doing today? 
 
     If yes, when and why?  ________________________________________________________ 
                                           _________________________________________________________ 
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Appendix B 
 
Letter for ALL Participant Recruitment 
Dear [Caregiver’s Name]: 
 
I am writing on behalf of the Pediatric Hematology/Oncology Division at Vanderbilt 
Children’s Hospital, which is currently studying leukemia (ALL) in childhood and the 
factors that may influence children’s quality of life after treatment. 
 
We know ALL therapy can cause immediate side effects like low blood counts, vomiting, 
and infections.  Researchers would like to learn more about the possible long-term effects 
from ALL therapy.  We are asking children 10-17 years of age who have completed 
treatment for ALL and their parents to participate in a study looking at the possible 
effects of chemotherapy on children’s memory, problem solving skills, and the ways that 
they manage their emotions. 
 
We are inviting you to participate in a study at Vanderbilt Children’s Hospital.  Taking 
part in this study involves two appointments scheduled on separate days.  You and your 
child can decide to participate in one or both parts of the study—it is completely up to 
you.  During the first appointment, you and your child would be asked to complete 
questionnaires regarding your child’s emotional and behavioral well-being and coping 
skills and to answer some questions about your child’s medical, school, and family life in 
an interview format.  That day your child would also be administered six tests to measure 
his/her memory and problem-solving skills.  If you decide to participate in this part of the 
study, we will give your child and your child’s primary caregiver $25 each as a thank-you 
for participating, and $10 to help offset some of the costs of travel.   
 
During the second appointment, your child would take a similar set of tests but this time 
they would complete the tests while our research team uses a scanner to take images 
(pictures) of his/her brain while responding to test items.  This is called functional brain 
imaging.  It is a procedure that uses a large magnet to take pictures of the brain to show 
how the brain works while it is actively responding to a test or other task.  In addition to 
the tests your child would watch 5 minutes of two movies to see how he/she responds to 
something that is emotional. If you decide to participate in this second part of the study, 
your child will receive and additional $25, and your child’s primary caregiver will be 
reimbursed another $10 for travel costs.   
 
There may or may not be a direct benefit to you or your child from taking part in this 
study.  Your child will receive a limited evaluation of his or her learning and thinking 
abilities, and you will be able to talk to a psychologist about the results.  We will also 
provide you a brief written summary of the test results that you may keep.  Because the 
research exam is different from a complete evaluation, it is possible that the psychologist 
would recommend further testing.  This wouldn’t be part of the study, but we would 
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identify options that are available to you and your child.  Overall, it is hoped that the 
information learned from this study may help future patients who have ALL. 
 
All of the information we collect for the study will be kept strictly coinfidential, and your 
name and your child’s name will not be used in any publication of our findings.  
Participating in this study is entirely voluntary and your decision to participate or not 
won’t change your relationship with our clinic or Vanderbilt Children’s Hospital.  Also, 
if you decide to participate, you may withdraw at any time without prejudice.   
 
Please feel free to call me at (615) 936-1762 if you have any questions or would like to 
participate.  Otherwise, I will call you in several days to answer any questions you may 
have and determine if you are willing to participate. 
 
Best Regards, 
 
 
 
 
Sue Alisanski, M.D.  
 87
Appendix C 
 
 
Informed Consent Forms 
 
 
This informed consent applies to parents/guardians of children 10-17 years old. 
 
Name of participant: 
_______________________________________________________ Age: ___________ 
 
The following is given to you to tell you about this research study.  Please read this form with care 
and ask any questions you may have about this study.  Your questions will be answered.  Also, 
you will be given a copy of this consent form.   
 
You do not have to be in this research study. You may choose not to be in this study 
without changing your healthcare, services or other rights.  You can stop being in this 
study at any time.  If we learn something new that may affect the risks or benefits of this 
study, you will be told so that you can decide whether or not you still want to be in this 
study.     
 
1. What is the purpose of this study?  
 
You are being asked to take part in this research study because your child was treated 
for Acute Lymphocytic Leukemia (ALL) at Vanderbilt Children’s Hospital. The treatments 
used for ALL may affect children’s memory, learning, attention, thinking, and reasoning.    
 
The goals of this study are:  
 
• To look at neurobehavioral function (in other words, thinking function, learning 
abilities, and behavior) in patients previously treated for ALL. 
• To see if other factors (such as gender, age at diagnosis, and how long it has been 
since the patient’s cancer treatment) are associated with greater neurobehavioral 
problems in patients treated for ALL; and  
• To find if there is a connection between neurobehavioral problems and a patient’s 
happiness with life.  
 
2. What will happen and how long will you be in the study? 
 
 Taking part in this study involves two parts:  
 
 Part I: 
• taking several tests to see if your child has any learning or memory problems which 
may have developed as a result of the cancer and its treatment;  
• filling out a survey to see how happy your child is with his/her life; 
• this part of the study will take approximately 3 ½ hours. 
 
Part II: 
• having images taken of your child’s brain while he/she is performing certain memory 
and problem-solving tasks and watching two scenes from a movie that are tense or a 
little bit scary.  The images will be taken by a magnetic resonance scanner, which 
uses magnetic fields to take pictures of the brain; 
• this part of the study will take you and your child about 3 hours.  
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In addition, we would like to collect some medical information from your child’s medical 
records about how your child’s child cancer diagnosis and treatment and whether your 
child is currently free of cancer and other major medical illnesses.  By signing this form, 
you are giving us permission to extract this information from your child’s medical record. 
 
3. Costs to you if you take part in this study: 
 
There will be no cost to you or your insurance plan if your child takes part in this study.  
 
4. Side effects and risks that you can expect if you take part in this study: 
    
Your child may find some of the tests boring or tiring. Your child may also become frustrated 
because some portions of the testing are difficult. The testing may find that your child has 
problems in thinking, learning, or behavior.  
 
This information could be distressing to you or your child. If your child is found to have results 
that are lower than expected, the doctor will strongly recommend further testing and will 
assist you with a referral to an appropriate provider.  
 
Participants with the following may not be able to have an MRI: implanted medical devices 
such as aneurysm clips in the brain, heart pacemakers and cochlear (inner ear) implants, 
iron-based tattoos, pieces of metal close to or in an important organ (such as the eye). 
Certain metal objects like watches, credit cards, hairpins, writing pens, etc. may be damaged 
by the MRI scanner or may be pulled away from the body in the MRI room. Also, metal can 
sometimes cause poor pictures if it is close to the part being scanned. For these reasons, 
patients are asked to remove these objects before going into the MRI room.  
 
Your child will hear "hammering" noises while the scanner is preparing for scanning and 
taking the pictures. Earplugs will be given to help reduce the noise. Your child may also feel 
some vibration and some slight movement of the table during the test.   
 
In this study, the fMRI scan is used for research purposes only.  However, in the event that 
an abnormality is found, you will be told and encouraged to consult your child’s doctor. 
 
5. Risks that are not known: 
 
There are no unknown risks as a result of taking part in this study.    
 
6. Payment in case you are injured while in this study: 
      
Immediate necessary care in the rare case of an adverse event will be provided at Vanderbilt 
University without charge if you are injured because of participation in this research project.  
Vanderbilt will neither provide for the costs of further treatment beyond immediate necessary 
care nor provide monetary compensation for such injury. 
 
7. Good effects that might result from this study:  
   
a) The benefits to science and humankind that might result from this study are: What we 
learn from this study may help future patients who have leukemia.  
 
b) The benefits you might get from being in this study are: You and your child may or not 
benefit from taking part in this study. The study evaluation may find problems in thinking, 
learning, or behavior in your child that may otherwise not have been found. The psychologist 
will discuss the findings of the evaluation directly with you. You will also be given a typed 
report that will be yours to keep and to share, if you choose, with others who have an interest 
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in your child’s well-being (such as your child’s teacher). We want to stress that this is a 
research evaluation and not a comprehensive clinical assessment. Further testing may be 
needed to obtain a complete picture of your child’s strengths and as well as the appropriate 
recommendations for possible services.  
 
8. Other treatments you could get if you decide not to be in this study: 
   
You may choose not to have your child take part in this study. You may want to discuss this 
with your child’s regular doctor as well as other trusted personal and family advisors.  
 
  
9. Payments for your time spent taking part in this study or expenses: 
 
You and your child will each receive $25 as a thank-you gift for participating in Part I of the 
study. Your child will receive $40 as a thank-you gift for participating in Part II of the study 
and you will be given $10 to cover the cost of travel, parking, meals or other costs incurred to 
come for the testing.  
 
10. Reasons why the study doctor may take you out of this study: 
   
There are no known reasons why your doctor would take your child out of this study.  
However, if your child is taken out of the study, you will be told the reason. 
 
11. What will happen if you decide to stop being in this study? 
 
You can remove your child from the study or your child can decide to withdrawal at any time. 
You can either tell the research assistant working with you at ANY time during Part 1 or 2 of 
the study or you can call Principal Investigator Bruce Compas, Ph.D. at 615-322-8306. 
 
 
12. Who to call for any questions or in case you are injured: 
   
If you have any questions about this research study or if you feel your child has been hurt by 
being in this study, please feel free to contact Project Coordinator Laura Keys at 615-343-
8720 or Principal Investigator Bruce E. Compas, Ph.D. at 615-322-8306.  
 
For additional information about giving consent or your rights as a person in this study, 
please feel free to call the Vanderbilt University Institutional Review Board Office at (615) 
322-2918 or toll free at (866) 224-8273, or email at 
http://mcapps01.mc.vanderbilt.edu/IRB/WkshpReg.nsf/Suggestion Form?OpenForm.  
 
13. Confidentiality:   
 
All reasonable efforts will be made to keep your child’s protected health information (PHI) private 
and confidential. PHI is individually identifiable health information that is, or has been collected or 
maintained by Vanderbilt University Medical Center (VUMC), including information that is 
collected for research purposes only, and can be linked back to you or your child.  Using or 
sharing (“disclosure”) such information must follow federal privacy guidelines.  
 
By signing the consent document for this study, you are giving permission (“authorization”) for the 
uses and disclosures of your personal health information.  A decision to participate in this 
research means that you agree to let the research team use and share your child’s PHI as 
described below.  
 
As part of the study, Dr. Compas and his study team may share the results of your child’s study 
test results and non-study related information about your child’s diagnosis and treatment, as well 
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as portions of your child’s medical record, with the groups named below. These groups may 
include representatives from the Federal Government Office for Human Research Protections 
and the Vanderbilt University Institutional Review Board.  Federal privacy regulations may not 
apply to these groups; however, they have their own policies and guidelines to assure that all 
reasonable efforts will be made to keep your child’s personal health information private and 
confidential.  
 
The study results will be retained in your child’s research record for at least six years after the 
study is completed.  At that time, the research information not already in your child’s medical 
record will be will be destroyed. Any research information entered into your child’s medical record 
will be kept indefinitely. 
 
Unless otherwise indicated, this permission to use or share your child’s PHI does not have an 
expiration date. If you decide to withdraw your permission, we ask that you contact Dr. Compas in 
writing and let him know that you are withdrawing your permission. His mailing address is: 
Vanderbilt University, Department of Psychology & Human Development, Peabody College #512, 
230 Appleton Place, Nashville, TN  37203.  At that time, we will stop further collection of any 
information about your child.  However, the health information collected prior to this withdrawal 
may continue to be used for the purposes of reporting and research quality. 
 
A decision to not participate in this research study will not affect your child’s treatment, 
payment or enrollment in any health plans or affect your eligibility for benefits. You will 
receive a copy of this form after it is signed.  
 
STATEMENT BY PERSON AGREEING TO PARTICIPATE IN THIS STUDY 
 
Please  
 
[  ] I have read this consent form and all my questions have been answered. 
 
[  ] The information in this consent form has been explained to me and all my 
questions have been answered. 
 
[  ] I freely and voluntarily choose to participate in this study.  I understand that I may 
withdraw at any time. 
 
[  ] I freely and voluntarily choose to take part only in Part I of this study 
(psychological testing and completing questionnaires). 
 
[  ] I freely and voluntarily choose for my child to take part in Part II of this study (brain 
imaging study). 
 
[  ] I freely and voluntarily choose to allow my child participate in this study.  I 
understand that my child may withdraw at any time and I may withdraw my child at 
any time. 
 
[  ] I freely and voluntarily choose to allow the research team to contact me by 
telephone or mail about future research studies examining psychological issues 
related to childhood cancer.   
 
 
            
Date    Signature of patient/volunteer     
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Consent obtained by:  
 
  
            
Date    Signature    
 
            
    Printed Name and Title  
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This assent document applies to children 10-17 years old. 
 
Name of participant                                                        Age                    
 
Below are the answers to some of the questions you may have.  If you have any questions about 
what is written below or have any other questions about this research, please ask them.  You will 
be given a copy of this consent form.   
 
1. Why are you doing this research? 
 
You received medicine to help treat your leukemia.  The drugs you got can sometimes have 
side effects.  Some side effects show up right away (like being tired) and others show up 
later.  Not everyone has these side effects, but some people might.  All kids are different.   
 
Doctors want to know if kids who have had leukemia treatment have any trouble with things 
like remembering, learning new things, or paying attention, and this is why we are doing this 
research. 
 
2. What will I do and how long will it take? 
 
We are asking you to take some skills tests.  This will take about 3 ½ hours.  We are also 
asking you to take some tests while you are in a machine that is able to take pictures of your 
brain.  This is called “brain imaging.” The machine will take pictures to show how your brain 
works while you take the tests and while you watch some short movie scenes.  The movie 
scenes might be a little bit scary.  This second part of the study takes about 3 hours. 
 
As a thank-you for participating, you will get $25 for taking the skills tests and another $40 for 
doing the second part of the study where we use a machine to take pictures of your brain.      
 
3. Do I have to be in this research study and can I stop if I want to? 
 
You can choose whether or not you want to be in this research study.  You can also stop at 
ANY time.  You can skip a question or a test if you want to and nobody will be mad at you.  
You can also choose to do just one part of the study. 
 
4. Could it make me sick [or sicker]? 
 
No, but sometimes testing can be a little tiring or difficult.  You can take breaks between tests 
if you start feeling tired or frustrated. 
 
5. Will anyone know that I am in this research study? 
 
No.  Your answers will be kept private.  Only the people working on our study will see your 
tests and forms.  Your name will not be on any of the tests.   
 
6. How will this research help me or other people? 
 
This research will help doctors find out if cancer drugs affect how kids learn and think.  This 
research could help future leukemia patients.  Also, the results of the study might help find 
some areas of thinking and learning that are more difficult for you.  If this happens, we would 
tell you and your parents how to find out more about these problems. 
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7.   Who do I talk to if I have questions?  
  
If you have any questions about this research study, you can ask your doctors now, or you 
can call Dr. Bruce Compas (615) 322-8306 or Dr. Debbie Van Slyke at (615) 936-0272. 
 
 
[  ] I would like to do Part I of this study (skills tests). 
 
[  ] I would like to do Part II for this study (brain imaging). 
 
 
 
            
Date    Signature of patient/volunteer     
 
 
 
Assent obtained by:                     ___________________________________________________ 
           Signature                                                 Printed Name and Title  
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This informed consent applies to parents/guardians of children 10-17 years old. 
 
Name of participant: _________________________________________________________ 
Age: ___________ 
 
The following is given to you to tell you about this research study.  Please read this form with care 
and ask any questions you may have about this study.  Your questions will be answered.  Also, 
you will be given a copy of this consent form.   
 
You do not have to be in this research study. You may choose not to be in this study without 
changing your healthcare, services or other rights.  You can stop being in this study at any time.  
If we learn something new that may affect the risks or benefits of this study, you will be told so 
that you can decide whether or not you still want to be in this study.     
 
1. What is the purpose of this study?  
 
We are conducting this study to learn about the development of learning, memory, and 
problem-solving skills during childhood and adolescence.  We are also interested in how 
these areas of thinking are related to the ways in which they handle their emotions. In 
addition to generally healthy participants like your child, we are also asking people who 
were treated for childhood cancer to be in this study because we want to learn about how 
their treatment may effect their cognitive development.  We will be comparing results 
from healthy participants and childhood cancer survivors to see if there are differences in 
thinking, learning, and coping between these two groups.    
 
2. What will happen and how long will you be in the study? 
 
 Taking part in this study involves two parts:  
 
 Part I: 
• taking several tests of learning, memory, and problem-solving 
• filling out a survey to see how happy your child is with his/her life; 
• this part of the study will take approximately 3 ½ hours. 
 
Part II: 
• having images taken of your child’s brain while he/she is performing certain memory 
and problem-solving tasks and watching two scenes from a movie that are tense or a 
little bit scary.  The images will be taken by a magnetic resonance scanner, which 
uses magnetic fields to take pictures of the brain; 
• this part of the study will take you and your child about 3 hours.  
 
3. Costs to you if you take part in this study: 
 
There will be no cost to you or your insurance plan if your child takes part in this study.  
 
4. Side effects and risks that you can expect if you take part in this study: 
    
Your child may find some of the tests boring or tiring. Your child may also become frustrated 
because some portions of the testing are difficult. The testing may find that your child has 
some difficulty in thinking, learning, or behavior.  
 
This information could be distressing to you or your child. If your child is found to have results 
that are lower than expected, we will assist you with a referral to an appropriate provider who 
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can do further testing, as the testing for this study is not a comprehensive battery that can be 
used by itself for clinical purposes. 
 
Participants with the following may not be able to have an MRI: implanted medical devices 
such as aneurysm clips in the brain, heart pacemakers and cochlear (inner ear) implants, 
iron-based tattoos, pieces of metal close to or in an important organ (such as the eye). 
Certain metal objects like watches, credit cards, hairpins, writing pens, etc. may be damaged 
by the MRI scanner or may be pulled away from the body in the MRI room. Also, metal can 
sometimes cause poor pictures if it is close to the part being scanned. For these reasons, 
patients are asked to remove these objects before going into the MRI room.  
 
Your child will hear "hammering" noises while the scanner is preparing for scanning and 
taking the pictures. Earplugs will be given to help reduce the noise. Your child may also feel 
some vibration and some slight movement of the table during the test.   
 
In this study, the fMRI scan is used for research purposes only.  However, in the event that 
an abnormality is found, you will be told and encouraged to consult your child’s doctor. 
 
5. Risks that are not known: 
 
There are no unknown risks as a result of taking part in this study.    
 
6. Payment in case you are injured while in this study: 
      
Immediate necessary care in the rare case of an adverse event will be provided at Vanderbilt 
University without charge if you are injured because of participation in this research project.  
Vanderbilt will neither provide for the costs of further treatment beyond immediate necessary 
care nor provide monetary compensation for such injury. 
 
7. Good effects that might result from this study:  
   
What we learn from this study may help future children and adolescents with learning or other 
school-related problems. 
 
8. Other treatments you could get if you decide not to be in this study: 
   
You may choose not to have your child take part in this study.  
 
9. Payments for your time spent taking part in this study or expenses: 
 
You and your child will each receive $25 as a thank-you gift for participating in Part I of the 
study. Your child will receive $40 as a thank-you gift for participating in Part II of the study 
and you will be given $10 to cover the cost of travel, parking, meals or other costs incurred to 
come for the testing.  
 
10. What will happen if you decide to stop being in this study? 
 
You can remove your child from the study or your child can decide to withdrawal at any time. 
You can either tell the research assistant working with you at ANY time during Part 1 or 2 of 
the study or you can call Principal Investigator Bruce Compas, Ph.D. at 615-322-8306. 
 
11. Who to call for any questions or in case you are injured: 
   
If you have any questions about this research study or if you feel your child has been hurt by 
being in this study, please feel free to contact Project Coordinator Laura Keys, M.S. at 615-
343-8720 or Principal Investigator Bruce E. Compas, Ph.D. at 615-322-8306. 
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For additional information about giving consent or your rights as a person in this study, 
please feel free to call the Vanderbilt University Institutional Review Board Office at (615) 
322-2918 or toll free at (866) 224-8273, or email at 
http://mcapps01.mc.vanderbilt.edu/IRB/WkshpReg.nsf/Suggestion Form?OpenForm.  
 
14. Confidentiality:   
 
All reasonable efforts will be made to keep the personal information in your research  
record private and confidential but absolute confidentiality cannot be guaranteed.   
Your information may be shared with institutional and/or governmental  
authorities, such as the Vanderbilt University Institutional Review Board and the  
Federal Government Office for Human Research Protections; however, they have  
their own policies and guidelines to assure that all reasonable efforts will be  
made to keep your child’s personal health information private and confidential.  
 
The study results will be retained in your child’s research record for at least six years  
after the study is completed.  A decision to not participate in this research study will  
not affect your child’s treatment, payment or enrollment in any health plans or affect  
your eligibility for benefits. You will receive a copy of this form after it is signed.  
 
STATEMENT BY PERSON AGREEING TO PARTICIPATE IN THIS STUDY 
 
Please  
 
[  ] I have read this consent form and all my questions have been answered. 
 
[  ] The information in this consent form has been explained to me and all my 
questions have been answered. 
 
[  ] I freely and voluntarily choose to participate in this study.  I understand that I may 
withdraw at any time. 
 
[  ] I freely and voluntarily choose to take part only in Part I of this study 
(psychological testing and completing questionnaires). 
 
[  ] I freely and voluntarily choose for my child to take part in Part II of this study (brain 
imaging study). 
 
[  ] I freely and voluntarily choose to allow my child participate in this study.  I 
understand that my child may withdraw at any time and I may withdraw my child at 
any time. 
 
[  ] I freely and voluntarily choose to allow the research team to contact me by 
telephone or mail about future research studies examining psychological issues in 
children and adolescents   
 
 
            
Date    Signature of volunteer     
 
 
Consent obtained by:  
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Date    Signature    
 
            
    Printed Name and Title  
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This assent document applies to children 10-17 years old. 
 
Name of participant                                                           Age                    
 
Below are the answers to some of the questions you may have.  If you have any questions about 
what is written below or have any other questions about this research, please ask them.  You will 
be given a copy of this consent form.   
 
1. Why are you doing this research? 
 
We are interested in studying how kids’ and teens’ thinking changes as they get older.  All 
kids are different in how their brains develop, and we want to see how brain development is 
connected to how they learn and remember new things, how they solve problems, and how 
they deal with their feelings.  In addition to healthy kids like you, we are also asking people 
who were treated for cancer when they were young to participate in this study to see if the 
treatment they got has any effect on their thinking and learning. 
 
2. What will I do and how long will it take? 
 
We are asking you to take some skills tests.  This will take about 3 ½ hours.  We are also 
asking you to take some tests while you are in a machine that is able to take pictures of your 
brain.  This is called “brain imaging.” The machine will take pictures to show how your brain 
works while you take the tests and while you watch some short movie scenes.  The movie 
scenes might be a little bit scary.  This second part of the study takes about 3 hours. 
 
As a thank-you for participating, you will get $25 for taking the skills tests and another $40 for 
doing the second part of the study where we use a machine to take pictures of your brain.      
 
3. Do I have to be in this research study and can I stop if I want to? 
 
You can choose whether or not you want to be in this research study.  You can also stop at 
ANY time.  You can skip a question or a test if you want to and nobody will be mad at you.  
You can also choose to do just one part of the study. 
 
4. Could it make me sick? 
 
No, but sometimes testing can be a little tiring or difficult.  You can take breaks between tests 
if you start feeling tired or frustrated. 
 
5. Will anyone know that I am in this research study? 
 
No.  Your answers will be kept private.  Only the people working on our study will see your 
tests and forms.  Your name will not be on any of the tests.   
 
6. How will this research help me or other people? 
 
This research will help us figure out how kids and teens learn and think.  In the future it could 
help people who have learning and other school-related problems.   
 
7.   Who do I talk to if I have questions?  
  
If you have any questions about this research study, you can call the Project Coordinator 
Laura Keys (615) 343-8720 or the Principal Investigator Dr. Bruce Compas (615) 322-8306. 
 
 99
 
[  ] I would like to do Part I of this study (skills tests). 
 
[  ] I would like to do Part II for this study (brain imaging). 
 
 
 
            
Date    Signature of volunteer     
 
 
 
Assent obtained by:                    ___________________________________________________ 
               Signature    Printed Name and Title  
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Appendix D 
 
 
Sample Letters Recruiting Healthy Control Participants 
 
 
Sample Letter Mentioning ALL Participant’s Name and Cancer Treatment 
 
Date 
 
Name 
Address 
 
Dear <name>: 
 
 We are writing to invite you and your child to participate in a study of child 
development being conducted by the Department of Psychology and Human 
Development at Vanderbilt University.  Your child was nominated for this study by 
<name of patient>.  <Name of patient> is participating in this study because <he/she> 
was treated for cancer as a child. The purpose of the study is to help determine if there 
are long-term effects of cancer treatment on attention, memory, problem solving skills, 
and managing emotions.  It is important that we are able to compare children and 
teenagers who have had cancer with those who have not had cancer.  Your participation 
would be as part of the group of children and teenagers in the study who have not had 
cancer. 
 
 Participation in the study involves coming to the Department of Psychology and 
Human Development twice.  During the first visit you and your child would complete 
several questionnaires and your child would take several brief tests of memory, attention, 
and problem-solving skills.  This session would take approximately 90 minutes and you 
and your child would receive $25 as a token of our appreciation for your participation.  
Your child would then participate in a second session at Vanderbilt in which they would 
respond to similar tests of memory, attention, and problem solving while pictures of their 
brain are taken in a neuroimaging scanner.  This session would take approximately 90 
minutes and your child would again receive $25. 
 
 If you are interested in participating in this study or in learning more about the 
study please call 615-343-8720 and ask for Laura Keys or email Laura Keys at 
laura.l.keys@vanderbilt.edu. 
 
Sincerely, 
 
 
 
Bruce E. Compas, Ph.D.    Laura L. Keys, M.A.. 
Patricia and Rodes Hart Professor   Doctoral Student 
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Sample Letter Not Mentioning Cancer Treatment 
 
Date 
 
Name 
Address 
 
Dear <name>: 
 
 We are writing to invite you and your child to participate in a study of child 
development being conducted by the Department of Psychology and Human 
Development at Vanderbilt University.  Your child was nominated for this study by 
<name of patient>, who is currently participating in this study. The purpose of the study 
is to examine attention, memory, problem solving skills, and managing emotions in 
adolescents.   
 
 Participation in the study involves coming to the Department of Psychology and 
Human Development twice.  During the first visit you and your child would complete 
several questionnaires and your child would take several brief tests of memory, attention, 
and problem-solving skills.  This session would take approximately 90 minutes and you 
and your child would receive $25 as a token of our appreciation for your participation.  
Your child would then participate in a second session at Vanderbilt in which they would 
respond to similar tests of memory, attention, and problem solving while pictures of their 
brain are taken in a neuroimaging scanner.  This session would take approximately 90 
minutes and your child would again receive $25. 
 
 If you are interested in participating in this study or in learning more about the 
study please call 615-343-8720 and ask for Laura Keys or email Laura Keys at 
laura.l.keys@vanderbilt.edu. 
 
Sincerely, 
 
 
 
Bruce E. Compas, Ph.D.    Laura L. Keys, M.S. 
Patricia and Rodes Hart Professor   Doctoral Student 
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Sample Anonymous Letter 
 
Date 
 
Name 
Address 
 
Dear <name>: 
 
 We are writing to invite you and your child to participate in a study of child 
development being conducted by the Department of Psychology and Human 
Development at Vanderbilt University.  Your child was nominated for this study by a 
classmate who is currently participating in this study. The purpose of the study is to 
examine attention, memory, problem solving skills, and managing emotions in 
adolescents.   
 
 Participation in the study involves coming to the Department of Psychology and 
Human Development twice.  During the first visit you and your child would complete 
several questionnaires and your child would take several brief tests of memory, attention, 
and problem-solving skills.  This session would take approximately 90 minutes and you 
and your child would receive $25 as a token of our appreciation for your participation.  
Your child would then participate in a second session at Vanderbilt in which they would 
respond to similar tests of memory, attention, and problem solving while pictures of their 
brain are taken in a neuroimaging scanner.  This session would take approximately 90 
minutes and your child would again receive $25. 
 
 If you are interested in participating in this study or in learning more about the 
study please call 615-343-8720 and ask for Laura Keys or email Laura Keys at 
laura.l.keys@vanderbilt.edu. 
 
Sincerely, 
 
 
 
Bruce E. Compas, Ph.D.    Laura L. Keys, M.S. 
Patricia and Rodes Hart Professor   Doctoral Student 
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Appendix E 
 
 
Advertisement for Recruiting Healthy Control Participants 
 
 
Neurocognitive Development in Children and Adolescents Study 
 
Children, adolescents, and young adults between the ages of 10 and 20 are needed for a 
research project to help us better understand the development of learning, memory, and 
problem-solving skills.  We are also interested in how these areas of thinking are related 
to the ways in which young people handle stress and their emotions.  There are two parts 
to this study which require two separate visits to Vanderbilt University Medical Center.  
The first part involves completing questionnaires and taking several tests of learning, 
memory, and problem-solving.  The second part involves having images taken of your 
child’s brain in a magnetic resonance scanner (MRI) while performing certain skills tests 
and watching two scenes from a movie.  This will help us understand which parts of the 
brain are involved in the development of thinking and ability to handle emotions.  
Participants can choose to be in one or both parts of the study. 
 
Compensation of $25 each for the young participant and parent is provided for the first 
part of the study.  For the second part of the study, the young participant will be 
compensated $40.  Parents will also be compensated an additional $10 to help with the 
cost of travel. 
 
Interested individuals should contact: 
Laura Keys, M.S. by telephone: (615) 343-8720 or email: laura.l.keys@vanderbilt.edu 
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